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ABSTRACT 
Objective: Fermentable oligosaccharides, disaccharides, monosaccharides and polyols 
(FODMAPs) are a group of carbohydrates that evade digestion in the small intestine 
and are subsequently metabolized by colonic microbiota. Colonic fermentation of 
FODMAPs has been linked to a prebiotic effect resulting in improved blood glucose 
response and subjective appetite.  The purpose of this study was to examine how 
changes in FODMAP consumption effects blood glucose response and subjective 
appetite.  Fasting breath hydrogen was also examined as an indicator of colonic 
fermentation.   
Design: This study utilized a single blind, randomized, crossover design.  Healthy 
participants (n=16) were instructed to follow a low-FODMAP and high-FODMAP 
diet for a period of three days separated by an 11-day “washout period.”  Fasting and 
post-prandial blood glucose were assessed via Cholestech.  Subjective appetite was 
analyzed through use of visual analogue scales. Data were analyzed via repeated 
measures analysis of variance.   
Results:  Blood glucose concentrations did not vary significantly between  the two 
dietary interventions (p=.111, η2 =.155). Reduced total area under the curve (TAUC) 
was seen after the high-FODMAP intervention, however, this decrease was not 
significant (6722±861 vs. 7149±1120 mg/dl*min, p=.178).  No significant changes in 
subjective appetite were noted. Fasting breath hydrogen did not vary significantly 
between the two interventions, however, was found to be inversely correlated with 
glycemic response (r=-0.54, p=.034).  Outcomes were reanalyzed utilizing only 
subjects consuming greater than 4 grams of FODMAPs during high-FODMAP 
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intervention.  Reduced post-prandial blood glucose response (F(1,7df)=7.21,p.007) and 
blood glucose TAUC was seen (t=3.60, p=.009) in this subset.  
Conclusion:  The High- FODMAP intervention resulted  in a non-significant 
reduction in blood glucose. However, poor dietary compliance likely explains this 
result. The inverse relationship seen between breath hydrogen and blood glucose 
TAUC indicate a potential prebiotic effect. Individuals compliant with high FODMAP 
diet did show reduced glycemic response. Further research, with larger samples and 
longer interventions, is needed. 
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PREFACE 
This manuscript was written to comply with the University of Rhode Island Graduate 
Manuscript Thesis Format.   This thesis contains one manuscript entitled “ The impact 
of High and Low- FODMAP Conditions on Blood Glucose Concentrations in Healthy 
Young Adults.”  This manuscript has been written in a form suitable for publication in 
The Journal of the Academy of Nutrition and Dietetics.   
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The impact of High and Low- FODMAP Conditions on Blood Glucose 
Concentrations in Healthy Young Adults 
 
Evan Kerr, Matthew Delmonico, Ingrid Lofgren, Kathleen Melanson 
Department of Nutrition and Food Sciences, University of Rhode Island  
Kingston, Rhode Island 02881 
ABSTRACT 
Objective: Fermentable oligosaccharides, disaccharides, monosaccharides and polyols 
(FODMAPs) are a group of carbohydrates that evade digestion in the small intestine 
and are subsequently metabolized by colonic microbiota. Colonic fermentation of 
FODMAPs has been linked to a prebiotic effect resulting in improved blood glucose 
response and subjective appetite.  The purpose of this study was to examine how 
changes in FODMAP consumption effects blood glucose response and subjective 
appetite.  Fasting breath hydrogen was also examined as an indicator of colonic 
fermentation.   
Design: This study utilized a single blind, randomized, crossover design.  Healthy 
participants (n=16) were instructed to follow a low-FODMAP and high-FODMAP 
diet for a period of three days separated by an 11-day “washout period.”  Fasting and 
post-prandial blood glucose were assessed via Cholestech.  Subjective appetite was 
analyzed through use of visual analogue scales. Data were analyzed via repeated 
measures analysis of variance.   
Results:  Blood glucose concentrations did not vary significantly between the two 
dietary interventions (p=.111, η2 =.155). Reduced total area under the curve (TAUC) 
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was seen after the high-FODMAP intervention, however, this decrease was not 
significant (6722±861 vs. 7149±1120 mg/dl*min, p=.178).  No significant changes in 
subjective appetite were noted. Fasting breath hydrogen did not vary significantly 
between the two interventions, however, was found to be inversely correlated with 
glycemic response (r=-0.54, p=.034).  Outcomes were reanalyzed utilizing only 
subjects consuming greater than 4 grams of  FODMAPs during high-FODMAP 
intervention.  Reduced post-prandial blood glucose response (F(1,7df)=7.21,p.007). and 
reduced blood glucose TAUC was also seen (t=3.60, p=.009) in this subset.  
Conclusion:  The High- FODMAP intervention resulted in a non-significant reduction 
in blood glucose. However, poor dietary compliance likely explains this result. The 
inverse relationship seen between breath hydrogen and blood glucose TAUC indicate 
a potential prebiotic effect. Individuals compliant with high FODMAP diet did show 
reduced glycemic response. Further research, with larger samples and longer 
interventions, is needed. 
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Introduction:  
Fermentable oligosaccharides, disaccharides, monosaccharides, and polyols 
(FODMAPs) are a class of short-chained carbohydrates that are prevalent in the 
modern diet 1,2.  Common dietary FODMAPs include oligosaccharides such as 
fructans (or fructooligosacchrides) and galactans (or galactooligosaccharides), 
disaccharides such as lactose, monomers such as fructose, and polyols such as sorbitol 
and mannitol 3.  FODMAPs are associated with common functional properties 
including: limited absorption in the small intestine, high osmotic activity, and  rapid 
fermentation by colonic microbiota 4-6.  Due to these functional properties, excess 
consumption of dietary FODMAPs has been linked to increased  incidence of diarrhea, 
flatulence, as well as abdominal pain and distension amongst individuals with irritable 
bowel syndrome (IBS) 2,7.  Diets decreasing FODMAP intake have shown  the ability 
to mitigate gastrointestinal symptoms and improve quality of life for individuals with 
IBS 8,9.   
While reducing dietary FODMAPs has proven to be an effective  means to 
manage IBS, long-term  use of a low- FODMAP diet could have adverse health 
consequences and  may not be appropriate for people without  IBS.  Low-FODMAP 
foods are generally considered to be high glycemic index (HGI) consisting of simple 
carbohydrates that are easily digested and absorbed 10.  Elevated  intake of HGI foods 
have been found to increase risk of metabolic disease, diabetes, and cardiovascular 
disease 10.  Conversely, high-FODMAP foods are associated with a low glycemic 
index (LGI)10.  These carbohydrates are not as readily absorbed by the small intestine. 
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Thus LGI foods reduce postprandial glycemic response, which is important regarding 
development of chronic diseases such as diabetes and heart disease 11. 
In addition to reduced  post-prandial glycemic response, LGI foods have 
demonstrated the ability to reduce glycemic response at subsequent meals 12,13.  This 
‘second meal effect’ is likely due to a prebiotic effect attributed to increased colonic 
fermentation 14-16.  Malabsorbed carbohydrates, upon entering the colon, are rapidly 
metabolized, via fermentation reaction, by the resident colonic microbiota. Short-chain 
fatty acids (SCFA), byproducts of anaerobic metabolism, interact with colonic 
epithelial cells and have been linked to increased post-prandial expression of 
numerous gut peptide hormones, most notably glucagon like peptide -1 (GLP-1), 
which has been shown to have an important role regarding the improvement of 
glycemic response 17,18.  Increased colonic fermentation, as measured by breath 
hydrogen, is inversely related to blood  glucose response 19,20.  Furthermore, colonic 
fermentation has been found to decrease post-prandial blood glucose response by as 
much as 15% amongst a healthy sample 21.  Increased colonic fermentation associated 
with consumption of FODMAP-dense foods indicates that FODMAPs have the 
potential to effect blood glucose response in a manner that is independent of glycemic 
index 12. However, a possible prebiotic effect associated with FODMAP specific 
interventions has not been examined.  
 Increased colonic fermentation has also been linked to decreases in subjective 
appetite ratings.  Supplementation of fructooligosaccharides has been found to 
promote expression of GLP-1, which leads to reduced ratings of subjective hunger in 
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both clinical and free-living settings 22,23.  Furthermore, increased colonic 
fermentation has been associated with decreased energy intake 24.  
Research, to this point, has indicated that increases in colonic fermentation of 
carbohydrates will reduce post-prandial blood glucose response.  However, these 
studies involved test meals or supplementation designed to deliver a targeted amount 
of oligosaccharides or soluble fibers. The ability of a FODMAP specific dietary 
intervention  to elicit this effect has not been examined. Furthermore, a possible 
prebiotic effect associated with increased FODMAP intake, in a free-living setting, has 
not been examined.  The present study examined how implementation of low- and 
high- FODMAP diets, in a free- living setting, would impact fasting and post-prandial 
glycemic response amongst healthy participants.  Additionally, this study examined 
how changes in dietary FODMAPs would affect subjective hunger, satiety and 
prospective consumption, in both fasting and post-prandial states.  Total FODMAP 
intake and fasting breath  hydrogen were analyzed as a means to determine dietary 
compliance.    
 Materials and Methods: 
Study Design: 
The study utilized a randomized, single-blinded, cross-over design that 
compared low and high-FODMAP diet-interventions in a free-living setting. Study 
design and laboratory procedures are outlined in figure 1. This study consisted of five 
separate data collection days.  Initial data collection (i.e. prior to any dietary 
intervention or outcome testing) consisted of screening, completion of informed 
consent, instruction regarding study protocol, anthropometrics, and body composition 
assessment (via BODPOD). Baseline data collection took place on a Tuesday and 
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required that the subject arrive at the laboratory following a 10-hour fasting period.  
Fasting anthropometrics, blood glucose, breath hydrogen and subjective appetite 
ratings were obtained.  A high FODMAP test meal (described below) was then 
administered and post-prandial blood glucose response and subjective appetite were 
measured at 30 and 60 min post consumption of the test meal. A 24-hour dietary recall 
was taken using the Nutritional Data System for Research (NDSR). At the conclusion 
of the 1-hour test period, individuals were randomly assigned to follow either diet 1 
(low- FODMAP) or diet 2 (high- FODMAP) for a period of three days. Subjects 
reported to the laboratory for post-intervention testing on the following Friday.  The 
post-intervention laboratory protocol was identical to that of baseline testing.  After 
post-intervention testing, subjects undertook an 11-day washout period and the 
protocol, with the alternative diet, was repeated beginning on the following Tuesday.  
Order randomization started with a coin flip for the first subject, and subjects altered 
order thereafter.     
 Subjects:  
 All subjects participating in this study were recruited as a convenience sample 
from the student population of the University of Rhode Island. Exclusionary criteria 
included gastrointestinal disorders such as: celiac disease, IBS, lactose or gluten 
intolerance, diverticular disease, colitis such as Cohn’s disease or ulcerative colitis and 
stomach ulcers. Additional exclusion criteria included currently following a weight 
loss diet, food allergies, smoking, pregnancy or lactation, diabetes, adrenal disease, 
kidney or bladder problems, a thyroid disease or currently taking any appetite 
suppressant medication. Subjects were advised to keep physical activity constant 
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throughout the course of the study.  The study was approved by the Institutional 
Review Board of the University of Rhode Island and subjects provided written 
informed consent prior to participating. 
Blood Glucose Analysis:  
 Blood glucose was analyzed at three separate time points during each 
laboratory session. Capillary blood from subjects fingers was sampled at 0 minutes 
(fasting), 30-minutes post-test meal, and 60-minutes-post test meal. Protocols for 
obtaining capillary blood samples were obtained from Alere Inc (Waltham, Ma).   At 
each time point, 40 µL aliquots of capillary blood were obtained and subsequently 
analyzed via Cholestech LDX (Alere Inc., Waltham MA).  
Assessment of Subjective Hunger, Satiety and Prospective Consumption:  
 Subjective appetite was assessed using 10-cm visual analog scales (VAS).  
During laboratory sessions subjects completed VAS questionnaires regarding satiety, 
hunger, and prospective food consumption. VAS has been determined to be an 
effective method for assessing these outcomes 25.  
Assessment of FODMAP Intake: 
 FODMAP intake was assessed through 24- hour recalls utilizing NDSR.  
Recalls were conducted using the NDSR software version 12 developed by the 
Nutrition Coordinating Center (NCC), University of Minnesota, Minneapolis. NDSR 
utilizes a multiple pass method described in full elsewhere 26.  All 4 dietary recalls 
reflected Mondays (pre-intervention) and Thursdays (post-intervention).   Total intake 
of fructose, lactose, and sugar alcohols were compiled from NDSR output files for 
analysis.  The extent to which dietary fructose and lactose are malabsorbed is highly 
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variable. Fructose is absorbed efficiently when consumed in equimolar amounts as 
glucose 27.  A healthy individual can consume between 25-50 grams of lactose before 
malabosrption can occur and was excluded from analysis 28,29.  Thus total FODMAP 
intake was considered fructose consumed in excess of glucose, and sugar alcohols.  
Oligosaccharide intake is not assessed by NDSR databases and to our knowledge is 
not available in any nutrient database reflecting the United States food supply.    
Breath Hydrogen: 
Fasting Breath hydrogen was assessed at all baseline and post-intervention data 
collection days.  Samples were collected with the QuinTron AveoSampler (QuinTron 
Instrument Co, WI, USA), as described elsewhere30.  Once obtained, samples were 
immediately analyzed utilizing the QuinTron Microlyzer- CM (QuinTron Instrument 
Co, WI, USA).  The instrument was calibrated 30 min prior to use, utilizing 98-PPM 
reference gas (QuinTron Instrument Co, WI, USA) 31.  Samples were collected in 
duplicate and the results were averaged.  
Anthropometrics: 
 All anthropometric measurements were obtained at the beginning of each 
laboratory session, after the subject had undergone a 10-hour overnight fast and had 
voided bladder. Height, weight, and waist circumference were all measured and BMI 
was calculated.  The protocol utilized for collection of anthropometric data has been 
described elsewhere 32.   
High- FODMAP Test Meal: 
 The test meal was designed to mimic free-living conditions. The 25g of 
FODMAPS associated with the test meal have been found to induce increases in 
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breath hydrogen concentration indicating carbohydrate malabsorption 8. The test meal 
consisted of: 2 pieces of whole grain bread, 1 tsp. of sugar free preserves, 1 tsp. of 
honey, 40 g of raisins, and 12 oz. of milk.  This meal consists of 478 kcal and 
contained 25g of FODMAPs per serving 
Implementation of Dietary Intervention: 
At the conclusion of baseline data collection, each subject was provided with 
educational materials and one on one verbal instruction (approximately 15 minutes in 
duration) regarding the dietary intervention to which he or she was assigned.  In order 
to ensure that the participants were unaware of the intervention to which they were 
assigned, the low- FODMAP and high- FODMAP interventions were referred to as 
“diet 1” and “diet 2” respectively.  Subjects were provided with a booklet to assist 
them with adherence to the high or low FODMAP conditions to which they were 
assigned. Dietary booklets were made specifically for the purposes of this study 
utilizing previous research studies 2,33-35. Outside of the laboratory setting no food of 
any kind was supplied to study participants.  
Power Calculations: 
Sample size calculations were performed based on differences in post-prandial 
blood glucose response seen in a previous study by Nilsson et al 20. This study found 
that peak blood glucose concentrations decreased 1± 0.3 mmol/L (18 ± 5 mg/dL) from 
control to experimental conditions. Calculations show an effect size of .333. All 
calculations were based on an alpha of 0.05 and power of 0.80, and were completed 
using G* Power (version 3.1.7). According to these calculations, a 8-person sample 
size would be adequate to achieve sufficient power.  
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Statistics: 
Statistical analyses were performed using SPSS, version 22.0 (IBM 
Corporation, Summers, NY, USA).  Analysis of skewness and kurtosis show that all 
outcomes met criteria for normality. Data were checked for outliers utilizing Grubbs 
test for outliers 36. All outcomes were analyzed using repeated measures analysis of 
variance (treatment x time). Post hoc t-tests were utilized where appropriate.  Partial 
eta squared (η2 ) was calculated to estimate effect size, with a small effect (.10), 
medium effect (.250), and large effect (.40) 37.  Paired t-tests were utilized to examine 
within treatment interactions (baseline and intervention). Total area under the curve 
(TAUC) was calculated for blood glucose as well as subjective appetite. Pearson 
correlations were utilized to examine relationships between dietary FODMAP intake 
and subjective appetite as well as breath hydrogen and blood glucose. Significance 
was considered at p< .05.  
Results: 
 
 A total of 20 participants were recruited and enrolled in the study. Four 
subjects withdrew from the study. One withdrew due to medical reasons unrelated to 
this study. Three subjects attended the initial screening visit, however, failed to 
complete the final four visits. Data obtained from the remaining 16 participants were 
utilized for analysis. Demographic information is presented in table 1.  There were no 
significant differences regarding demographic variables of individuals assigned to the 
two orders.  There was no evidence of an order effect regarding blood glucose at any 
time point as Treatment * order (F(1,12df)= .030, p=.865), time*order (F(1,12df)=.120, 
and treatment*time*order (F(1,12df)=.101, p=.904) interactions were all non-significant 
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Assessment of Dietary Compliance FODMAP Intake: 
Figure 2 shows FODMAP intake during the two interventions. There was a 
significant treatment effect between the two dietary interventions  (F(1,15df)=9.845, 
p=.007, η2 =0.395) as well as a significant treatment *time interaction (F(1,15df)=5.316, 
p=.033, η= 0.262).   Within treatments analysis showed a significant decrease in 
FODMAP intake under the low- FODMAP condition when compared to baseline 
(2.26± 3.00 grams to 0.52± 0.55, t=2.275, p=.038).  FODMAP intake during the high-
FODMAP intervention, increased, however, this increase was not significant (3.23± 
4.68 (g) to 5.04± 5.36, t= 1.044, p= .313). High-FODMAP diet resulted in a 
significant increase in dietary FODMAPs post-intervention, as compared to the low-
FODMAP diet (5.04±5.36 vs. 0.52±0.55 g respectively; t=-3.513, p=.003).  
Assessment of Dietary Compliance via Fasting Breath Hydrogen: 
 Data from one subject was determined to be an outlier and was excluded from 
analysis. High-FODMAP diet showed modest increases in breath hydrogen when 
compared to the low-FODMAP intervention (6.6 ±8.0 vs. 2.7±3.3 ppm).  There was a 
significant treatment effect (F(1,12)=6.282, p=.028, η2 = .344) however,  time and 
treatment* time trends were not significant (Time: p=.763, η2=.008; treatment*time: 
p=.539, η2 =.032). There were no within treatment effects noted (Low-FODMAP: 
t=1.426, p=.179, High- FODMAP: t=-.216, p=.833).  
 Blood Glucose: 
Two subjects were excluded from biochemical analysis due to abnormal blood 
glucose values.  Figure 3 compares blood glucose response during the low- and high-
FODMAP conditions. Following the high- FODMAP intervention, there was a non-
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significant reduction in blood glucose response 30 minutes following consumption of 
the test meal (124.64± 22.84 vs. 137.31±30.52 mg/dL, t=1.585, p=.137). Treatment 
and treatment* time interactions were also not significant, and had small effect sizes 
(F(1,13df)= 1.631, p=.224, η2=0.111 and F(1,13df)=2.391, p= 0.111, η2= 0.155, 
respectively).  Likewise, total AUC was modestly lower under the high-FODMAP 
condition (6722±861 vs. 7149±1120 mg/dl*min), however, these differences were not 
statistically significant (t=1.424, p=.178). Analysis with Pearson correlations showed 
that blood glucose response 30 minutes after the test meal were inversely correlated to 
fasting breath hydrogen levels during the high-FODMAP intervention (r=-.546, 
p=.043). Likewise, blood glucose TAUC, under the high-FODMAP condition was 
inversely correlated to fasting breath hydrogen (r=-.549, p=.034).   
Subjective Appetite: 
  Post-intervention analysis of subjective hunger showed no significant 
differences between the high and low-FODMAP diet.  Treatment (F(1,15df)=0.118, 
p=.736) and treatment*time (F(1,15df)=0.383, p=.685) trends were not significant.  
Under fasting conditions, subjective hunger, under the low-FODMAP intervention 
was significantly elevated over pre-intervention (50.94±27.08 vs 64.63±23.40 (mm), 
t=-2.554, p=.022).  Total area under the curve for subjective hunger is presented in 
table 2.  No significant differences between subjective ratings of satiety were seen 
between the high and low-FODMAP interventions.  Treatment (F(1,15df)=.004, p=.947, 
η
2
=.000) and treatment*time (F(1,15df)=.201, p=.819, η2=.013) were not significant with 
very small effect sizes. TAUC for subjective satiety was analyzed and no significant 
findings were noted. Comparison of post-intervention data regarding prospective 
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consumption showed non-significant treatment (F(1,15df)=996, p=.334, η2=.062) and 
treatment*time (F(1,15df)=.043, p=.958, η2= .003) interactions. No significant within-
treatment differences were seen regarding prospective consumption.  Total area under 
the curve for prospective consumption showed no significant differences between the 
high and low-FODMAP diet (table 2).  
Data analysis with dietary compliance: 
 Biochemical analysis was reassessed including individuals who were most 
compliant with the high-FODMAP dietary intervention.  Individuals who consumed 
less than 4 grams of dietary FODMAPs during the high FODMAP diet were excluded 
from this portion of the analysis. As a result, 8 participants were excluded from this 
portion of data analysis leaving a total of 8 participants for analysis.   
 Amongst 8 “compliant” participants, FODMAP intake was increased under the 
high FODMAP dietary intervention.  Analysis showed a highly significant Treatment 
effect (p=0.001, η2 = 0.829) and a non-significant treatment*time trend (F(1,7df)= 
4.101, p=0.082, η2=0.369).  Within treatment changes were not significant.  See 
Figure 4 for further analysis.  
 Amongst the 8 “non-compliant” subjects, FODMAP intake was not effected by 
the dietary interventions. Non-significant treatment and treatment * time trends 
(F(1,7df)= 0.082, p=.782, η2= .016 and F(1,7df)0.132, p=.731, η2=0.026).    Likewise 
there were no within treatment differences during the low and high FODMAP 
interventions (2.14±2.79 vs. 0.49±0.47 and 1.61±2.13 vs. 0.50± 0.31 respectively).   
Blood Glucose: 
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 Figure 5 shows blood glucose response amongst compliant participants. Blood 
glucose response was associated with significant treatment (F(1,7df)= 8.293, p=0.024, 
η
2
=.542), Time (F(1,7df)= 32.13, p<0.000, η2 =0.821) and treatment *time interaction ( 
F(1,7df)= 7.216, p=0.007, η2 = 0.508).  Post-prandial blood glucose response under high 
FODMAP conditions was significantly lower 30 min after test meal when compared to 
the low FODMAP diet (121.38±17.46 vs. 148.25±27.54: t=4.521, p=.003).  There 
were no within treatment differences amongst the two interventions. Paired t-tests 
showed a significantly lower TAUC response under high FODMAP conditions when 
compared to Low FODMAP conditions (249.56 ± 35.70 vs. 219.25± 2189, t=3.603, 
p=0.009).       
Subjective Appetite: 
 Analysis of subjective appetite amongst the compliant sample showed no 
significant post-intervention differences between the high and low-FODMAP 
interventions.  Regarding subjective hunger, treatment (F(1,7df)= 0.856, p=.386, η2= 
.109) and treatment*time (F(1,7df)= .494, p=.620, η2=.066) were not significant with 
small effect sizes. Significant within treatment differences, regarding subjective 
hunger, were seen 30 minutes after administration of the test meal under the high 
FODMAP intervention (14.13± 15.75 vs. 21.25± 16.64, t=-2.769, p=0.028).  Total 
AUC for subjective appetite did not show any differences between the high and low-
FODMAP diets and are listed in table 4.  Likewise, satiety was unaffected by the 
interventions as indicated by non-significant treatment (F(1,7df)= .140, p=.719 ,η2= 
.020) and treatment* time (F(1,7df)=0.872, p=.440, η2=.111) interactions.  Total AUC 
for subjective satiety was also unaffected.  Prospective consumption remained 
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unchanged throughout study as indicated by non-significant treatment (F(1,7df)=.372, 
p=.559) and treatment *time (F(1,7df)=.069, p=.933) interactions.  
Discussion: 
 
 Summary: 
 This study is novel because it was the first study to examine a possible 
prebiotic effect associated with a free-living, high-FODMAP diet.  The purpose of this 
particular study was to examine how changes in dietary FODMAP consumption, 
amongst a healthy sample, in a free-living setting, would affect blood glucose and 
subjective appetite ratings in both fasting and post-prandial conditions.   The results of 
this study indicate that there was limited dietary compliance during the high- 
FODMAP intervention.  This limited compliance resulted in non-significant 
differences regarding fasting breath hydrogen. There were no significant differences 
regarding blood glucose concentrations as a result of the dietary interventions.  Partial 
eta squared was calculated and indicated that there was a small effect size between the 
two interventions (0.155).  However, the negative correlation seen between breath 
hydrogen and blood glucose is suggestive of a prebiotic effect.   
 To examine a possible prebiotic effect associated with dietary FODMAPs 
individuals with the highest total FODMAP intake were analyzed. Significant 
decreases regarding blood glucose response were seen in the sample of compliant 
individuals. No changes significant regarding subjective appetite were seen in the 
sample compliant with the high-FODMAP diet.  
 Effect of FODMAP intake on blood glucose response: 
Fermentation of dietary carbohydrates by colonic microbiota has been found to 
influence blood glucose response through increased production of short-chain fatty 
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acids (SCFA).  SCFAs bind to L-cells lining the intestinal epithelium resulting in 
increased production of a variety of gut-peptide hormones, most notably glucagon-
like-peptide 138.  Previous studies have shown that supplementation of 
fructooligosaccharides can increase concentrations of GLP-1 in the proximal colon by 
50% 39. Binding of GLP-1 to beta cells increases expression of glucose transporters 
making the beta-cell more “sensitive” to the presence of extracellular glucose 40,41.  An 
increase in GLP-1 has been associated with increased activity of beta-cells in the 
presence of glucose 40,42.  Experimentally, increased endogenous production of GLP-1 
has been inversely associated with blood glucose response amongst a healthy 
sample20.   
The present study analyzed blood glucose across the sample of 16 participants; 
however, no significant differences between the two dietary interventions were seen.  
This was likely due, in part, to poor dietary adherence under high FODMAP 
conditions.  Amongst the sample of 16 subjects, the low FODMAP dietary 
intervention was successful in decreasing FODMAP intake from baseline assessment.  
Under the high FODMAP intervention, FODMAP intake increased by 4.52 grams 
over the low FODMAP diet. While this was a statistically significant difference, this 
discrepancy regarding FODMAP intake between the two diets was likely not large 
enough produce a prebiotic effect.   
Dietary compliance amongst the sample was also considered.  Individuals with 
the highest FODMAP intake throughout the high-FODMAP intervention (n=8) were 
analyzed.  Reanalysis of blood glucose for this sample showed a significantly reduced 
blood glucose response.  Furthermore, this sample showed reduced post-prandial 
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blood glucose response 30 minutes after administration of test meals.  Previous studies 
show similar changes in post-prandial glycemic responses; however, these 
interventions were associated with considerably more FODMAP intake 21,22.  
Brighenti et al.12 showed significantly reduced glycemic response amongst a sample 
consuming 5 grams of lactulose12.   However it should be noted that these studies 
involved supplementation of FODMAPs.  In order to achieve target FODMAP intake, 
individuals either consumed food in laboratory setting or were provided with food to 
consume outside of the laboratory settings.  This particular dietary intervention only 
utilized dietary instruction and all choices regarding FODMAP intake were made by 
the participant in a free-living setting. These results suggest that a prebiotic effect in 
the form of significant changes in post-prandial glycemic response can be achieved 
with relatively small changes in FODMAP intake.   
 Importantly, indications of a prebiotic effect were not evident in the 
noncompliant sample.  This sample consumed 0.50 grams of FODMAPs during the 
high FODMAP intervention, and no indication of a prebiotic effect was seen in the 
form of reduced glycemic response.   
 Determination of sample compliant with high-FODMAP diet: 
Assessment of FODMAP intake for dietary compliance was performed in 
accordance to previous research 4,33. The NDSR database utilized for quantification of 
FODMAP intake did not assess dietary oligosaccharides consumed. Assessment of 
total FODMAP intake included fructose, lactose, and sugar alcohols.  Fructose and 
lactose are considered to be conditional FODMAPs due to the variation regarding their 
absorption amongst healthy populations.   Fructose, for example, is absorbed through 
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two transport mechanisms: the GLUT 2 and GLUT 5 transporters. The GLUT 5 
transporter is specific for fructose, has a high affinity for the monosaccharide, 
however, its ability to absorb glucose is limited43. The GLUT 2 transporter absorbs 
fructose in conjunction with glucose; therefore dietary fructose is only completely 
absorbed when equimolar concentrations of glucose are present44,45.  Thus in order to 
be considered a dietary FODMAP, fructose intake had to exceed that of glucose 4,33.  
Lactose was not considered a FODMAP for the purposes of this study due to the 
selection criteria allowing only for individuals who had no diagnostic history of 
lactose intolerance and considered themselves able to consume lactose.   
 Breath Hydrogen: 
 In addition to SCFAs, hydrogen is another common byproduct of fermentation 
of malabsorbed carbohydrates. Hydrogen gas, produced in the colon, is absorbed 
through the walls of the intestine, entering the bloodstream, and is subsequently 
excreted as a component of exhaled breath46. Microbial fermentation of carbohydrates 
is considered the only means through which this “breath hydrogen” can be generated 
29
.  Breath hydrogen testing is a reliable method of measuring the extent to which 
carbohydrates are being malabsorbed and fermented 8,33,47.  Changes in breath 
hydrogen concentration are indicative of quantity of FODMAPs consumed and also 
the rate of digestion.   The ability of dietary FODMAPs to evoke a prebiotic effect has 
been intimately linked to changes in breath hydrogen 46.    This particular study found 
a non-significant increase in fasting breath hydrogen during the high- FODMAP 
intervention (2.11 vs. 6.36 ppm).   While statistical significance was not obtained, the 
breath hydrogen values obtained under high-FODMAP conditions approached the 
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upper limit of what would be expected for healthy individuals48.  Importantly, this 
study did find an inverse relationship between fasting breath hydrogen values and 
blood glucose response indicating a close relationship between increased colonic 
fermentation and glycemic response.  Furthermore, these findings are consistent to that 
of previous research20.   
 Effect of intervention on subjective appetite: 
Gut peptide hormones have also been shown to impact subjective appetite.  For 
example GLP-1 has also been shown to bind to afferent nerve fibers of the central 
nervous system resulting in increased feelings of satiety 40,42. Intravenous infusion of 
GLP-1 in a healthy human sample resulted in increased feelings of “fullness” and 
satiety that were not seen in the control group (p<0.03) 49.  Peptide PYY is another gut 
peptide hormone found to impact subjective appetite.  Obese individuals are subject to 
reduced endogenous PYY concentrations, and increases in endogenous PYY has been 
found to attenuate appetite50.  Cani et al.22 showed increased colonic fermentation 
associated with FOS supplementation resulted in increased GLP-1 and PYY, and 
subsequent reductions in subjective hunger after a standardized test meal 22.  A recent 
study regarding supplementation of fructans, in a free-living sample, reduced 
subjective hunger ratings in a dose dependent manner (p<0.03)23.  In the present study, 
there was no difference between the two dietary interventions regarding subjective 
appetite ratings perhaps due to insignificant dose.  
Strengths and limitations: 
 The crossover design of this study was a major strength since each individual 
served as his or her own control and eliminated possible inequities in experimental and 
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control groups that may exist in between group experimental designs.  All outcomes in 
this study (blood glucose, cholesterol, and subjective appetite) were measured utilizing 
validated instrumentation.   
 Possible limitations of this study include the use of NDSR to analyze 
FODMAP intake.  The inability of NDSR to quantify oligosaccharide consumption in 
our sample limited our ability to access dietary compliance.  Future studies may 
consider alternative methods of assessing FODMAP intake 51. Further limitations was 
our small sample of healthy participants, which limits the generalizability of our 
findings.  Further work my consider utilizing subjects with, or at risk of type two 
diabetes.  
 Conclusion: 
 The dietary intervention, utilized throughout this study, was unsuccessful in 
increasing FODMAP intake sufficiently to produce a prebiotic effect in the sample of 
16 healthy young adults.  However, when examining data from individuals consuming 
greatest quantities of FODMAPs during the high FODMAP period of the intervention, 
a potential prebiotic effect was encountered as seen in reduced postprandial blood 
glucose response.  This indicates a possible prebiotic potential of FODMAPs 
consumed in a diet of free-living individuals.  However, longer-term studies, with 
larger compliant samples are needed to confirm these results.      
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Table 1: Demographics, n=16 
Variable     
Female, n (%) 
Male, n (%) 
 
10 (62.5) 
6 (37.5%) 
Age (yr), M±SD 
 
20.47±1.77 
Body Weight (kg), M±SD 
 
63.85±11.65 
Body Mass Index (kg/m2), M±SD 
 
22.21±2.45 
Waist Circumference (cm), M±SD 78.98±7.57 
Body Fat Percent (%)*, M±SD 18.80±10.37 
 
*body fat percent obtained via BOD POD Body Composition 
   System (Life Measurement Instruments, Concord, Calif., USA)  
  
  
 
 
Figure 2: FODMAP consumption
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 (n=16) excluding the conditional FODMAP lactose.  Fructose was only 
Significant Treatment (F(1,14df)= 9.845, p<0.01, 
F(1,14df)= 5.315, p<0.05, η2= 0.262).  
 
Post-Intervention
High- FODMAP
Low-FODMAP
 
η2 =0.395) ) and 
  
A). 
      
 
 
B). 
       
 
Figure 3: A) Post-intervention blood glucose concentrations (Mean 
the curve.  Data is from n=14 subjects
determined by a repeated measures ANOVA (p=0.224 
a significant effect of time (p<.001). B)
treatment, time, and treatment by time interactions noted between the two treatments (p=0.31
respectively). 
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            Table 2. Subjective appetite expressed as TAUC1 (mean±sd) 
 
 
 
 
 
1:TAUC for visual analogue scales is expressed as (mm*min) for the sample of n=16 
2: indicates use of 2x2 repeated measures ANOVA. P-value and η2 are for treatment*time interaction 
  
  Low-FODMAP diet High-FODMAP diet ANOVA2 
 
Baseline Post ∆ Baseline Post ∆ p-value          η2 
Hunger 1635± 1041 1959± 806  324 1739±1059 2079±894  340   .655            .025 
      .819            .013 
 
     .958             .003   
Satiety 3516±865  3317± 839 -199 3615± 857 3279±1006  -336 
Prospective Consumption 1830± 1152 1796± 590      -34 1687± 800  2006± 765 328 
31
 
  
 
Figure 4: FODMAP intake (excluding conditional FODMAPs) n=8 
 
FODMAP consumption excluding conditional FODMAP lactose.  Fructose was only included when 
consumed in excess of glucose. Only includes individuals who were compliant (consumed >4 grams of 
FODMAPs as estimated from 24-hr Recall). Significant treatment effect (Treatment: F(1,7df)= 
33.875,p=0.001, ɳ2= 0.829). A non-significant treatment*time trend was noted (F(1,7df)= 
4.101,p=0.082, ɳ=0.369) 
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Figure 5: A) Blood glucose concentrations
conditions (Mean ±SD).  Data is from
FODMAP diet. Treatment, Time, and Treatment* time * interactions were all significant as determined 
by repeated measures ANOVA.  Post
significantly lower under high
under high-FODMAP conditions (p=.
* Indicates statistically significant decrease under high FODMAP conditions when compared to low 
(P<0.01).  
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          Table 3. subjective appetite expressed as TAUC1  
   
     1: TAUC for visual analogue scale is expressed as (mm*min) for the sample of n=8 
      2: indicates the use of 2x2 repeated measures ANOVA. P-value and η2 are for treatment*time interactions.  
 
 
  Low-FODMAP diet High-FODMAP diet ANOVA
2
 
 
Baseline Post 
∆ 
Baseline Post 
∆ 
p-value          η2 
Hunger 1830± 1152 1796± 590  -34 1687±800 2006±765 319   .344           .128 
      .135            .289 
 
     .462             .080  
Satiety 3476±1124 3810±414  -334 3960± 893 3650±700  -310 
Prospective Consumption 2023±1202 1996± 1042       -27 1850±1213  2150±1077  300 
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APPENDICIES 
 
A. REVIEW OF THE LITERATURE 
 
Overview: 
Approximately 100 trillion bacterial cells colonize the Human colon. 57.  
Recent research indicates that the metabolic activity of this colonic microbiota can 
make a significant contribution to the overall health and well being of the host 
organism 57,58.  Dietary components, mostly carbohydrates and some proteins, that 
evade digestion and absorption in the small intestine are subsequently deposited in the 
colon and are subject to the metabolic activity of the resident colonic microbiota. 
Research indicates that bacterial metabolism of dietary carbohydrates can have 
important implications regarding a wide variety of metabolic processes in the human 
body.   Fermentable oligosaccharides, disaccharides, monosaccharaides and polyols 
(FODMAPs) are a class of carbohydrate that evade enzymatic hydrolysis in the small 
intestine and are subsequently metabolized via fermentation by colonic microbiota7,59.  
The chemical properties of FODMAPS along with byproducts of their fermentation 
are known to exacerbate symptomology associated with certain functional 
gastrointestinal disorders, most notably irritable bowel syndrome (IBS)7,59,60.   
However, colonic fermentation of FODMAPs has also been linked to a number of 
health benefits most notably improved blood glucose response, decreased appetite, and 
prolonged periods of satiety.  Thus dietary FODMAPs could play an important clinical 
role regarding a wide variety of metabolic disorders.  
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Characteristics and Dietary Sources of FODMAPs: 
 Carbohydrates are a diverse class of macromolecule. Polymeric forms of 
carbohydrates are classified by molecular size, degree of polymerization, individual 
monomers making up polysaccharides, as well as the types of linkages between 
monomers61.  FODMAPs are often characterized by consisting of beta-glycosidic 
linkages with a low degree of polymerization (>10 subunits) distinguishing them from 
longer chained polysaccharides and dietary fibers60.  These unique short chain 
carbohydrates are common in a wide variety of foods that are often consumed in a 
modern western diet60,62.  Polymers of fructose, galactose, as well as sugar alcohols 
are amongst the most commonly consumed FODMAPs in a modernized diet 62. 
Fructans or fructo-oligosaccharides (FOS) are amongst the most common 
dietary FODMAPs 47,62. Dietary sources of FOS are wheat products, some fruits 
(apples and pears), as well as honey63.  Fructans are also commonly seen in grains and 
pasta products most notably wheat pasta, gluten-free pasta, and quinoa pasta1. The 
ability of the small intestine to absorb dietary FOS is severely limited 64.  
Experimental evidence indicates that up to 89% of ingested fructans reach the colon 
intact64.  Thus the energy production associated with fructans is estimated to be 9.5 
kJ/g which is about half of that of sucrose64. 
Galactans or Galacto-oligosaccharides are another common FODMAP present 
in modern diets.  Synthesized via enzymatic reaction from lactose, galacto-
oligosaccharides are composed of a chain of galactose monomers with a terminal 
glucose65.  GOS are associated with a degree of polymerization of between 2-8 
monomeric subunits65.  Beta-glycosidic bonds connecting these galactose monomers 
  37
result in 90% of ingested GOS passing through the small intestine to the colon66.  
Dietary sources of GOS include soy products, dried beans and peas, lentils humus, and 
are also associated with coffee consumption67.  The amount of GOS contained in the 
diet is highly variable and is often dependent on the intake of legumes61,62.  Galactan 
consumption is associated with a high prevalence of malabsorption in the small 
intestine and are thus categorized as FODMAPs.   
Consumption of sugar alcohols (polyols) has been growing in prevalence in 
modernized society. The human small intestine lacks enzymes capable of hydrolyzing 
or absorbing polyols and experimental evidence indicates that as much as 70 percent 
of ingested polyols are malabsorbed68.  Due to this high rate of malabosrption, polyols 
are considered to be a “low-calorie sweetener” providing approximately 2.4 kCals/g 69. 
Furthermore, polyols, such as sorbitol and mannitol have been associated with a 
similar “taste-profile” to other carbohydrates such as sucrose and are utilized 
commercially as a low calorie alternative to sucrose.  Sorbitol and mannitol are 
featured in a variety of products such as chewing gum, mints, tooth pastes, and 
sweetened beverages63,69.  Polyols also exist in nature in plants and function as 
osmoregulatory agents as well as an energy source 68.  Polyols are naturally derived 
from fruits such as apples, pears, and apricots and are associated with a variety of 
vegetables such as cauliflower, sweet corn, snow peas and mushrooms61,63,67.  
Malabsorption of FODMAPs: 
Malabsorption of macronutrients is regarded as the inability of the digestive 
system to enzymatically hydrolyze and absorb nutrients in the small intestine.  On one 
hand, carbohydrates associated with α-glycosidic linkages are readily absorbed by the 
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human body70,71.  Salivary and luminal hydrolase enzymes readily cleave these bonds 
allowing for absorption of these carbohydrates through transport proteins located in 
the first mucosal membrane of the small intestine70.  These hydrolase enzymes are 
unable, however, to hydrolyze the β-glycosidic linkages that are associated with 
FODMAPs, thus inhibiting digestion and absorption of these carbohydrates70.   
The lumen of the small intestine presents a substantial barrier regarding the 
rapid diffusion of large water-soluble molecules into enterocytes72.  While some 
absorption of dietary nutrients occurs through passive diffusion, the absorption of 
dietary carbohydrates is largely dependent on carbohydrate transporters located in the 
enterocytes of the small intestine 72.  Both active transport and co-transport 
mechanisms are employed as a means of absorbing dietary carbohydrates. These 
transport proteins are highly specific and are often limited in the amount of certain 
carbohydrates that can be absorbed.  For example, dietary fructose that is consumed in 
its monomeric form can also act as a “conditional” FODMAP.  Fructose can be 
absorbed through two mechanisms: GLUT-5 transporter and the GLUT-2 
transporter27. The GLUT-5 transporter is specific for fructose, however, its ability to 
absorb dietary fructose is limited27,48 .  While in the GLUT-2 transporter, fructose is 
absorbed in conjunction with glucose; therefore dietary fructose is only completely 
absorbed when equimolar concentrations of glucose are present 47. Thus diets that are 
associated with a fructose intake that exceeds that of glucose are associated with 
malabsorption. Even in healthy individuals, dietary consumption of fructose that 
exceeds 25 grams is often associated with malabsorption indicating that dietary 
fructose is only partially absorbed in the small intestine 7.  
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Osmotic Effect:  
 One of the most notable characteristics of dietary FODMAPs is their ability to 
exert an osmotic effect on the gastrointestinal system.  High quantities of dietary 
fructo-oligosaccharides, galacto-oligosaccharides, and polyols, act to draw water in to 
the lumen of the small intestine through simple diffusion 6,63.  Supplementation of a 
5% solution of mannitol in healthy individuals was shown to increase luminal small 
intestinal water concentration 50 mL, while supplementation of glucose was found to 
stimulate absorption of 147 mL of water in the small intestine (P<0.0001) 6.  The 
ability of dietary FODMAPs to exert this osmotic effect can have important 
implications regarding luminal distension, abdominal pain, and diarrhea that are 
associated with high levels of dietary FODMAPs2.   
 Barrett et al. 5 examined the osmotic effect of a high FODMAP meal in in 
subjects with ileostomy.  Throughout this analysis individuals consumed a high 
FODMAP test meal, and ileostomy effluent was collected and analyzed for FODMAP 
content.  Utilizing this “ileostomy model,” it was confirmed that an average of 32 % 
(95% CI, 6-73%) of FODMAPs consumed escape digestion in the small intestine 5. 
Furthermore, increases in FODMAPs found in ileostomy effluent were associated with 
a 22 % (95% CI, 5%-39%) increase in water content, indicating that malabsorbed 
carbohydrates are osmotically active 5,50.  This analysis confirms the ability of a high 
FODMAP diet to exert an osmotic effect on the small intestine and establishes a 
mechanism through which these carbohydrates can affect gastrointestinal tolerance. 
Influence of FODMAPs on Orocecal Transit: 
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 The ability of dietary FODMAPs to exert an increased osmotic effect can have 
important implications regarding orocecal transit.   The ability of FODMAPs to draw 
water into the lumen of the intestine results in increased peristaltic activity increasing 
the rate at which food travels through the gastrointestinal tract 73.   Ingestion of 25g of 
fructose and 5 g of sorbitol was found to have a significantly higher rate of intestinal 
transit when compared to control (P= 0.0033)73.  Furthermore, the length of 
carbohydrate polymers was found to significantly effect orocecal-transit.  Short chain 
carbohydrates (degree of polymerization >10), that are malabsorbed, have been found 
to have reduced orocecal transit times when compared to longer chained carbohydrates 
(degree of polymerization <10)74.  This shows that FODMAP consumption can alter 
the function of the small intestine and deliver ingested nutrients to the colon at a 
higher rate than longer chained, less osmiotically active carbohydrates.     
 Rapid Fermentation of Malabsorbed FODMAPs:   
Malabsorbed carbohydrates are subsequently deposited in the proximal colon 
where they serve as substrate for microbial metabolism.  Colonic microbiota utilize 
fermentation reactions to metabolize FODMAPs, which is characterized by increases 
in hydrogen gas formed in the colon.  In conditions associated with low dietary 
FODMAP consumption, production on hydrogen gas by colonic micro flora is low.  
However, increases in dietary FODMAPs will result in measurable increases in 
hydrogen production 75,76.  Hydrogen gas that is formed through this process is 
absorbed through the wall of the colon where it enters the blood stream.  Once it enters 
the blood stream, the hydrogen gas is subsequently excreted through the lungs 75,76.  
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Thus any changes in breath hydrogen concentrations can be attributed to colonic 
fermentation 75,76.   
Due to their short-chain length and ability to exert an osmotic effect, dietary 
FODMAPS are readily fermented by colonic microbiota.  The ability of a 
carbohydrate to exert an osmotic force is inversely proportional to its degree of 
polymerization77. Thus the ability of FODMAPs to draw fluids in to the lumen of the 
small intestine enhanced over longer chained polysaccharides77.  This increase in 
osmotic force “increases surface area available for enzymatic attack” making 
FODMAPs more susceptible to bacterial metabolism78.   A recent single blind 
crossover analysis showed that FODMAP consumption significantly influenced breath 
hydrogen levels (low FODMAP diet, 43 ±18 vs. high FODMAP diets 181± 79ppm; 
P<0.0001) 34. Changes in breath hydrogen concentration are indicative of quantity of 
FODMAPs consumed and also the rate of digestion 75,79.    Thus measurement of 
breath hydrogen can have important applications when assessing an individual’s post-
prandial physiological response to FODMAP consumption.   
Role of FODMAPs in IBS: 
The poor digestion, osmotic effect and high rate of bacterial metabolism that 
characterize dietary FODMAPs have important implications regarding symptomology 
associated with irritable bowel syndrome. FODMAP metabolism has been found to 
induce luminal distension, abdominal pain, bloating, and distension2. Diets that 
minimize FODMAP consumption have been associated with reduction in symptoms 
associated with IBS37.  Staudacher et al.37 found that 76% of IBS patients (n=43) 
placed on a low FODMAP diet reported improvements in symptoms when compared 
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to a healthy control group (49%; P< 0.001) 37.  Another analysis showed that long-
term implementation of a low FODMAP diet resulted in significant clinical 
improvements in 81% of IBS patients over a one month period9.  This clinical 
improvement was maintained in 66.7 % of patients 9. Symptomatic relief is directly 
correlated to decreased levels of breath hydrogen suggesting that carbohydrate 
malabsorption could be clinically significant in the provocation of gastrointestinal 
symptoms 9,34.   
Potential prebiotic effect of FODMAPs: 
  There is a multitude of different species and strains of bacteria that colonize 
the human colon.  Some species of microbiota such as bifidobacteria and lactobacilli 
are beneficial to the overall health of the host organism yet others (eg. Clostridium) 
can negatively affect the overall health 80. Consumption of poorly digested 
polysaccharides and oligosaccharides have shown to promote the development of 
these types of “healthy” colonic microbiota.  Gibson and Roberfroid 81 defined 
prebiotics as ‘non-digestible food ingredients that selectively stimulate growth and/or 
activity of one or a limited number of bacteria in the colon, thereby improving host 
health’ 81.  These alterations in the colonic microbiota can have important implications 
regarding a number of risk factors regarding development of metabolic disease80. 
  The ability of FOS to exert a prebiotic effect has been studied rather 
extensively. FOS supplemented in bacterial culture of 21 different strains of 
bifidobacterium was associated with significant bacterial growth.  Almost all of the 
strains of bifidobacterium were able to grow on a medium containing FOS, while only 
8 strains were able to show significant growth on mediums containing the longer chain 
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inulin 82.  Fructooligosaccharides have also proven to be an effective prebiotic in 
human models as well.  Fecal bacterial concentrations, in humans, were found to have 
a dose-dependent relationship regarding oligofructose supplementation (p<. 009) 83.  
This indicates that supplementation of FOS can be advantageous regarding cultivation 
of colonic bacterium that are regarded as beneficial for human health.   
While not studied as extensively as FOS, GOS supplementation, in healthy 
human populations, has also been associated with a significant probiotic effect.  
Supplementation of 10 grams of GOS throughout a 21 day intervention period showed 
a significant increase in breath hydrogen accompanied by increases in bifidobacterium 
84
.   More recently, supplementation of 10grams of GOS for a 10 day period was found 
to have significant increase concentrations of colonic microbiota (P<0.0001) 84.  These 
results were not seen with longer chain starches and fibers indicating that the low 
degree of polymerization associated with GOS can more effective prebiotics than 
longer chain fibers83.    
 Due to poor gastrointestinal tolerance, polyols research regarding a possible 
prebiotic effect is lacking.  Polyols, such as sorbitol, are associated with similar 
chemical properties as other FODMAPs such as GOS or FOS, thus a possible 
prebiotic effect associated with colonic fermentation of polyols cannot be ruled out. In 
vitro analysis has shown that supplementation of sorbitol to bacterial media results in 
increased bacterial proliferation, most notably increases in lactobacilli, which are 
largely considered to a beneficial species of colonic microbiota 85.    Furthermore, 
sorbitol supplementation in rats has been associated with a prebiotic effect as well.  
Supplementation of sorbitol over a 16-day period in rats resulted in significant 
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increases in lactobacillus 86.   While a direct link between polyol consumption and a 
prebiotic effect in humans has yet to be established experimentally, thus this area of 
study warrants further research.    
Prebiotics and Short-Chain Fatty Acids and Gut peptide hormone production:   
 Prebiotics are considered to be beneficial to the overall health of the host 
organism through the ability of these carbohydrates to cultivate the growth of 
favorable species of colonic microbiota.  As previously stated, high levels of 
bifodobacterium and lactobacilli are associated with health.  One of the main 
hypothesis through which these species of colonic microbiota are able to elicit this 
beneficial response is through production of short chain fatty acids (SCFA)87,88.  
Short-chain fatty acids are a byproduct of anaerobic metabolism of dietary 
carbohydrates.  Experimental evidence indicates that SCFA production through 
bacterial fermentation is linked increased serum concentrations of gut peptides such as 
glucagon- like peptide 1 and peptide YY 89.  Increases in these peptides have been 
associated with enhanced insulin sensitivity, increased feelings of satiety, and reduced 
energy intake43. 
 Glucagon- like peptide 1 (GLP-1) is known to influence a wide variety of 
metabolic processes throughout the body 44.  GLP-1 is released by L-cells located in 
the intestine in response to food intake 44. GLP-1 has shown the ability to confer 
insulin sensitivity through binding to pancreatic beta cells 43.  Binding of GLP-1 to 
beta cells increases expression of glucose transporters making the beta-cell more 
“sensitive” to the presence of extracellular glucose 43,44.  An increase in GLP-1 has 
been associated increased activity of beta-cell in the presence of glucose 43,45.  
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Furthermore, GLP-1 has also been shown to bind to afferent nerve fibers of the central 
nervous system resulting in increased feelings of satiety43,45.  GLP-1 is an important 
modulator of metabolic homeostasis and has potential to promote decreased energy 
intake and weight loss 43,45.  
Modulation of colonic microbiota through prebiotic supplementation can have 
important implications regarding post-prandial circulations of GLP-1.  Increases in the 
SCFA acetate and propionate concentrations have been shown to stimulate circulating 
concentrations of GLP-1 in mice 89.  Furthermore, increases in GLP-1 were associated 
with subsequent improvements in glucose tolerance and oxidative stress90. Cani et al 
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, utilizing an animal model, examined the physiological effect of FOS when 
supplemented in to a high fat diet.  FOS supplementation was found to increase 
concentrations of GLP-1 in the proximal colon by 50% 42.  This increase in GLP-1 
was associated with a reduction of energy intake and weight loss at the conclusion of 
the 15-day intervention42. Increases in plasma GLP-1 concentrations have also been 
associated with increased glucose tolerance18.  Furthermore, animals lacking the 
cellular receptor for GLP-1 were associated with hyperglycemia and weight gain 
despite FOS supplementation18.  This shows that GLP-1 has an important role 
regarding postprandial metabolic homeostasis.  
Increases in serum concentrations of GLP-1 has also proved to be important in 
humans.  Flint et al. 54 examined the effect of intravenous infusion of GLP-1 on 
subjective hunger in a healthy human sample.  The experimental group experienced 
increased feelings of “fullness” and satiety that were not seen in the control group 
(p<0.03) 54. Furthermore, increases in GLP-1 was associated with a 12% decrease in 
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energy intake (p=0.002) as well as reductions in blood glucose (p<0.002)54 Thus 
increasing post- prandial GLP-1 concentrations can have important health connotation 
most notably increased glucose sensitivity, reduced energy intake, and subsequent 
weight loss18,42.   
 Peptide YY (PYY) is another important gut-derived hormone that is known to 
influence energy intake and may be stimulated by prebiotics 44.  Like GLP-1, PYY is 
secreted by L-cells in the small ileum and colon in response to meal intake.  PYY has 
been shown to induce post-prandial satiety55 and circulating levels of PYY have been 
shown to influence size and timing of meals 55.  Furthermore, reduced levels of PYY 
have been shown to increase incidence of obesity, and restoration of PYY 
concentration to normal post-prandial levels attenuates appetite55.  Supplementation of 
gel-forming fibers has been associated with increases in circulating  PYY 91.  Over a 
three-week intervention, healthy individuals supplemented PolyGlycopleX, a 
manufactured soluble dietary fiber.  Supplementation of this fiber significantly 
increased PYY concentrations over the intervention period and was inversely 
correlated with blood glucose (r= -0.27,P=0.046) 91.  While this analysis did not show 
a decrease in weight or energy intake amongst participants, it does provide an alternate 
mechanism through which supplementation of prebiotics can induce health benefits 91.   
 Supplementation of sugar alcohols has also proven effective regarding 
increasing serum concentrations of PYY 92.  Lactitol supplementation, in male Wister 
rats, was found to significantly increase postprandial PYY concentrations when 
compared to the control group and was also associated with subsequent decrease in 
energy intake92.  Furthermore, supplementation of lactitol was associated with a 
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decrease of colonic pH through accumulation of SCFA through fermentation of 
malabsorbed lactitol by colonic microbiota.  Supplementation of lactitol in humans 
significantly increased breath hydrogen production (indicator of colonic fermentation) 
when compared to the sucrose consuming control92.  This analysis did not show 
increased PYY concentrations in humans as a result of lactitol supplementation; 
however, polyol supplementation did attenuate postprandial decreases in serum PYY 
concentrations that were seen with the control 92. 
 Cani et al. 22 showed that FOS supplementation amongst a healthy human 
population can significantly increase breath hydrogen and gut peptide hormone 
concentrations resulting in a subsequent reduction in subjective hunger ratings.  This 
analysis determined that increased colonic fermentation associated with prebiotic 
supplementation was associated with significant increases in GLP-1 and PYY 
concentrations after a standardized test meal22.  These increases in GLP-1 and PYY 
were associated with lower subjective hunger ratings as compared to the control 
group.  Furthermore, postprandial GLP-1 concentrations were significantly correlated 
with breath hydrogen excretion (r=0.85, p=0.007) while postprandial blood glucose 
concentrations were determined to be inversely correlated with breath hydrogen (r=-
0.73, -=0.02) 22.  This indicates that colonic fermentation of malabsorbed 
carbohydrates (prebiotics) can significantly increase postprandial concentrations of gut 
peptide hormones, most notably GLP-1 and PYY, which can translate in to reduced 
glycemia and hunger ratings amongst a healthy human sample22.     
Glycemic Index, Colonic Fermentation and Blood Glucose:  
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 Glycemic index (GI) is defined as “blood glucose-raising potential of a 
standard quantity of carbohydrate, compared with a glucose control” 93,94.  Reduced 
glycemia associated with a low GI diet is most likely related to the rate at which 
carbohydrates are absorbed.  Carbohydrates with a high glycemic index are easily 
absorbed and will result in rapid increases in postprandial blood glucose 
concentrations.  Carbohydrates with a low glycemic index are often malabsorbed and 
thus reduce postprandial glucose levels. Malabsorbed portions of low GI meals are 
subject to colonic fermentation and been linked to diminished insulin and blood 
glucose responses which is often accompanied by prolonged periods of satiety as well 
as reduced subjective hunger ratings 13,95.   
 One of the most important health benefits associated with consumption of LGI 
foods is the ability of these foods to promote “a second meal effect.”  A concept, 
originally described by Jenkins et al. 95 and Wolever et al 13 states that the glycemic 
index of an initial meal is a determinant of the postprandial physiological response at 
subsequent meals13-15,95.  During a one day test period, healthy volunteers, who were 
administered a LGI “breakfast” were found to have diminished insulin and post 
prandial blood glucose responses after administration of a HGI lunch 4 hours later15.  
A follow- up study found a similar relationship between glycemic index and 
postprandial blood glucose response at subsequent meals14. While these studies were 
not able to establish a relationship between colonic fermentation and improved 
glucose tolerance, LGI foods containing large amounts of poorly absorbed 
carbohydrates have the potential to improve glucose tolerance, a concept supported by 
subsequent research 14,15. 
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 A series of studies performed by Nilsson et al 16,19,21 were able to establish a 
direct relationship regarding glycemic index, colonic fermentation and subsequent 
postprandial physiological response.  These studies explored whether glycemic index 
of an evening meal would effect physiological response following a standardized 
breakfast.  Results showed that low GI meals resulted in increases in breath hydrogen 
when compared to the control (p=0.026).  Furthermore, blood glucose response was 
reduced following the low GI meal when compared to the control (p=0.019).  A follow 
up study by Nilsson et al.21 was able to showed that blood glucose response was 
inversely correlated with breath hydrogen values (r=-0.27; p<0.05) as well as GLP-1 
(r=-0.26;p<0.05)39.  Subjective ratings of satiety were found to be positively correlated 
with breath hydrogen (r=-0.27; p<0.01)21.   These studies establish a strong connection 
between colonic fermentation, thus increased microbial metabolism of poorly digested 
LGI foods, and improved postprandial responses in a healthy adult population. 
 More recently, a study was conducted examining the possible second meal 
effect associated with consuming a meal of brown beans.  Brown beans are not only 
considered to be a low GI food, they are also associated with over 8 grams of soluble 
fiber, 6 resistant starch, and 3 grams of raffinose (a common galactooligosaccharide) 
per portion of brown beans20.  Supplementation of these brown beans, amongst a 
healthy population, proved to be readily metabolized by colonic microbiota.  Breath 
hydrogen, utilized as an indicator of colonic metabolism, increased 141% compared to 
the control (p<0.01)20.  These increases in colonic fermentation were also associated 
with subsequent increases in the short-chain fatty acids proprionate (16% p<0.05) and 
isobutyrate  (18%; p<0.01).  In addition, satiety mediating hormones were increased as 
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a result of the brown bean meal (PYY increased 51%; p<0.001) and post-prandial 
blood glucose was significantly reduced (-15%;p<0.01) after a standardized HGI test 
meal20. Finally, subjective hunger ratings were 15 % lower in the experimental group 
than the control group (p<0.05).  This analysis links colonic fermentation with 
improvement of important cardiometabolic markers.   
 Brighenti et al. 12 examined how colonic fermentation of indigestible 
carbohydrates supplemented into sponge cake would effect glycemic response at 
subsequent meals.  This analysis utilized a cross-over design in which subjects 
randomly consumed three types of sponge cake varying in carbohydrate content.  The 
control for this analysis was a high glycemic index sponge cake, containing an easily 
digested amylopectin starch.  The second sponge cake was made with LGI amylose 
starch.  The third meal consisted of a sponge cake containing similar ingredients to the 
HGI control, however, 5 grams of lactulose was added in place of amylopectin.   
Lactuose is a synthetically derived disaccharide that is malabosrbed and subsequently 
fermented by colonic microbiota 12.  Results showed that the LGI and HGI-Lactulose 
interventions resulted in similar postprandial blood glucose responses when compared 
to the HGI meal.  Improved glucose tolerance was noted in both interventions and 
significant increases in breath hydrogen were seen (p<0.001 for both LGI and HGI-
Laculose).  This analysis shows that colonic fermentation of carbohydrates, 
independent of glycemic index, can improve subsequent glycemic response post meal 
12
.   
Colonic Fermentation and Subjective Hunger and Energy Intake: 
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The ability of dietary FODMAPs to reduce postprandial insulin and glucose 
responses is important regarding their ability to induce prolonged periods of satiety96.  
Meals that are high in glycemic index are associated with a sharp increase in blood 
glucose immediately following meal consumption followed by a drastic decrease in 
blood glucose 2 hours following the meal96.  This sharp decline in blood glucose levels 
has been linked to feelings of hunger and has been seen to immediately precede meal 
initiation.  A meal associated with a low glycemic index does not induce the drastic 
increases in blood glucose that are seen with HGI meals providing prolonged feelings 
of satiety.  HGI meals were found to increase subjective appetite scores by as much as 
44% amongst a population of obese females 96.  Thus the ability of LGI meals to 
reduce postprandial glycaemia can have beneficial impact regarding appetite 
sensations and potentially energy intake.   
Studies regarding FODMAPs in an animal model have shown that dietary 
FODMAPs can have important implications regarding hunger and overall energy 
intake.   Supplementation inulin and β-glucan in to the diet of mice resulted a 30% 
(inulin) and 37% (β-Glucan) reduction in energy intake resulting in a weight reduction 
amongst the sample 97.  The experimental group experienced increased concentrations 
of GLP-1, which was attributed to the increases in SCFAs 97.  Consumption of 
fructans in human populations has also shown to reduce subjective hunger ratings.  
Peterson et al.23 showed that supplementation of fructans in a healthy human 
population reduces subjective hunger ratings in a dose dependent manner (p<0.03) 
under free-living conditions.   
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 Consumption of dietary FODMAPs has also been shown to mediate energy 
intake.  Rosen et al.24 determined that a cereal based breakfast that is high in 
indigestible carbohydrates were associated with an “increased feeling of fullness” and 
a “lowered feeling of hunger and desire to eat”.  Furthermore, this study observed a 16 
% decrease in voluntary energy intake amongst participants after ingesting cereal that 
is high in indigestible carbohydrates.  Colonic fermentation of indigestible 
carbohydrates was observed through significant increases in breath hydrogen which 
were found to be inversely correlated with participant “desire to eat” (r=-0.24; 
p=0.053).  Breath hydrogen was also inversely correlated with voluntary energy intake 
at subsequent meals (r=-0.34,p=0.005).  Colonic fermentation of dietary FODMAPs 
can have important implications regarding mediation of energy intake and more 
research is needed to determine if weight loss implications exist for obese individuals.   
Colonic Fermentation, SCFA, and Potential to regulate cholesterol synthesis: 
 Elevated serum cholesterol levels are considered to be a primary determinant 
regarding the onset and progression of cardiovascular disease.  Total cholesterol levels 
exceeding 240 mg/dl have been associated development of cardiovascular disease98.  
The American Heart Association reports that an estimated 13.8% of the population 
(31.9 million individuals) meet this criteria98.  Elevated cholesterol levels, most 
notably LDL, contribute to endothelial dysfunction in cardiovasculature increasing 
risk of atherosclerotic development.  While effective pharmacological means of 
lowering cholesterol have been proven effective, dietary interventions have proven 
advantageous as well.  Many dietary interventions center around increases in soluble 
dietary fibers, which, decrease dietary cholesterol absorption through promotion of 
  53
bile excretion. However, increases in serum short chain fatty acids (SCFA) produced 
through colonic fermentation of prebiotics have shown the ability to attenuate hepatic 
cholesterol synthesis through modification of regulatory enzymes, most notably 
Adenosine 5’- monophosphate activated protein kinase (AMPK) as described in the 
following sections.   
Metabolic Functions of AMPK: 
AMPK is a serine/ threonine kinase and is an important regulatory protein that 
acts to modulate cellular energy homeostasis 99,100.  Increases in AMPK activity is 
associated with low cellular energy concentrations (high AMP/ATP ratio). Thus 
AMPK acts to increase cellular glucose concentrations through activation of GLUT 4 
transporters (increasing cellular glucose uptake) and has also been linked to up-
regulation of cellular glycolysis through activation of 6-phosphofructo- 2 kinase and 
fructose-2,6-bisphosphatase 99,100.  AMPK helps to maintain cellular homeostasis, in 
times of energy depletion, through up-regulation of catabolic (energy producing) 
processes.   
AMPK also inhibits anabolic processes (energy consuming pathways) from 
occurring, most notably hepatic cholesterol synthesis.   Research indicates that AMPK 
has the ability to inhibit cholesterol synthesis in a similar fashion to statins 101. 
Cholesterol is synthesized from acetyl-CoA subunits through a complex metabolic 
pathway in which HMG-CoA reductase catalyzes the rate-limiting reaction 102,103.  
HMG-CoA reductase catalyzes the conversion of 3-hydroxy-3-methylglutyl-CoA to 
mevaloate, a highly endergonic reaction that requires NADH as a cofactor102,103.  
HMG-CoA reductase is subject to enzymatic inhibition through phosphorylation of the 
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Serine-872 residue103.  This reaction, catalyzed by AMP-activates protein kinase 
(AMPK) inhibits the binding of the NADH cofactor to the protein, rendering the 
protein non-functional103.  
 
Short Chain Fatty acids and AMPK activity: 
 
Increases in serum concentrations of SCFA have been associated with 
increases in the activity of hepatic AMPK 102.  While the mechanism through which 
SCFAs promote the activity of AMPK has yet to be elucidated, it has been 
hypothesized that SCFAs increase the AMP/ATP ratio resulting in the subsequent 
activation of AMPK 102. Research by Kawaguchi et al.104 and Sakabibera et al.105 
suggest that supplementation of acetate in mice resulted in increased activity of 
hepatic AMPK.  These studies indicated that SCFAs have the ability to directly 
increase catalytic activity of AMPK104,105.   
Fushimi et al 106 showed that supplementation of SCFA can be directly related 
to decreased rate of cholesterol synthesis.  This study examined the effect of 
supplementation of acetate in a sample of rats.  The analysis showed that 
supplementation of acetate was associated with decreased hepatic concentrations of 
malonyl- COA indicating inhibition of HMG- COA reductase106.  This analysis 
indicates that increases in serum concentrations of SFCA can prove advantageous 
regarding reduction in cholesterol synthesis.   
Short Chain Fatty Acids and Bile synthesis: 
An alternate mechanism through which SCFAs can impact serum cholesterol 
levels is through increased hepatic bile synthesis. Bile acids, synthesized in the liver, 
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are excreted after a meal and function to facilitate the digestion and absorption of 
lipids44,107.  While bile is composed of a variety of organic compounds, bile acids and 
free cholesterol are considered to be a main component 44. Excretion of bile acids is 
the primary means through which excess cholesterol is removed from the body44. 
Thus, increasing hepatic synthesis of bile will likely result in an increased rate of 
excretion of free cholesterol. SCFAs have shown the ability to increase bile synthesis 
through up regulation of cholesterol 7α-hydroxylase (CYP7A1)102. The CYP7A1 
enzyme catalyzes the conversion of cholesterol to 7α-hydroxycholesterol which is 
regarded as a rate limiting step regarding bile acid synthesis44,108.   The rate of 
synthesis of bile acids is considered to coincide with the enzymatic activity of 
CYP7A1 44.  Studies have shown that mice lacking the CYP7A1 gene are often 
associated with hyperlipidemia and are also associated with elevated LDL cholesterol 
108
.  Supplementation of SCFAs has shown to increase activity of CYP7A1 and 
attenuate hyperlipidemia in animal models109.  Fushimi et al 109 found that 
supplementation of acetate in rats increased rate of bile excretion and was found to 
exert hypolipidemic effects on the experimental sample despite being fed a high 
cholesterol diet109. 
Colonic fermentation, SCFAs, and cholesterol synthesis in Humans: 
In the context of a normal human diet, increases in SCFA are achieved through 
colonic fermentation of prebiotics. Colonic fermentation of carbohydrates, and 
subsequent increases in SCFA, have been associated with improvements in blood 
lipids in humans.  Brighenti et al.110 examined how consuming a breakfast meal, 
containing 18% inulin (a known prebiotic) would effect blood lipid values in healthy 
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males throughout a 4 week intervention.  The analysis showed that supplementation of 
inulin resulted in statistically significant increase in breath hydrogen, which is a 
primary indicator regarding the occurrence of colonic fermentation of carbohydrates 
(test:280±35; placebo 78±26 ppm, p<0.05)110.  These changes in breath hydrogen 
concentrations were associated with decreases in total cholesterol and triacylglycerols 
amongst the experimental group110.  Furthermore, the intervention was determined to 
be negatively correlated with blood lipid concentrations, and positively correlated with 
secondary bile acid excretion110.   
 Colonic fermentation of carbohydrates has also proven beneficial amongst a 
hypercholestererolemic population.  Supplementation of 6 grams of β-glucan per day 
over a 6-week period resulted in a significant decrease in total cholesterol and LDL 
cholesterol when compared to the control group52.  Other studies have shown that soy 
products containing an added prebiotic resulted in significant reductions in LDL 
cholesterol (=0.18±0.07mmol/l,p=0.042) and improve the LDL/HDL ratio 
(0.28±0.11,p=0.41)53.  While this body of research is incomplete, there is promising 
evidence regarding the efficacy of increased SCFA through dietary interventions 
amongst both healthy and at-risk populations.   
 In conclusion, colonic fermentation of dietary carbohydrates has been linked to 
a wide variety of health benefits.  Most notably, colonic fermentation of dietary 
carbohydrates has been linked to increases in colonic production of short-chain fatty 
acids. Increases in SCFA have been subsequently linked to increases in gut peptide 
hormones, most notably GLP-1 and PYY, resulting in increased insulin sensitivity and 
reduced post-prandial blood glucose response.  Colonic fermentation of fermentable 
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carbohydrates has also been linked to prolonged periods of satiety and has been 
implicated in reducing energy intake.  Increases in SCFAs through colonic 
fermentation have also been associated with decreases in blood lipid concentrations in 
both healthy and at-risk populations.  Most literature regarding this area of study has 
been conducted through research in animals, and research that has been performed in 
humans has been subject to high variability.  Further research is needed to determine 
how FODMAPs, when incorporated into a ‘free-living diet’, can effect colonic 
fermentation, SCFA concentrations, and subsequent physiological response. 
  
  58
B. METHODOLOGY 
Overview: 
The methodology for this particular study was developed in the Energy 
Balance Laboratory in the department of Nutrition and Food Sciences, at the 
University of Rhode Island.  Data collection for this study took place during the 
spring/summer of 2013. This study utilized a randomized, single- blind, crossover 
design to measure pre- and post-prandial physiological responses of healthy 
individuals exposed to both high and low FODMAP diets. After baseline data was 
collected, participants were carefully instructed on the incorporation of high or low 
FODMAP conditions into their normal, free-living diet.  Breath hydrogen, blood 
glucose, appetite and satiety were assessed in the subject under fasting and post-
prandial conditions after practicing the diet for a period of three days.  Following 
an 11-day washout period, subjects then underwent above stated laboratory 
procedures under opposite FODMAP conditions.      
 Subjects: 
Subjects for this study were recruited from the student population at the 
University of Rhode Island.  They were recruited as a convenience sample through 
classroom announcements, university e-mail, and flyers.  To participate in this 
study, subjects had to: be healthy (free from chronic diseases such as celiac 
disease, IBS, diabetes mellitus, or colitis), between the ages of 18-48, not currently 
following a weight loss diet, no clinical history of functional gut disorders, non-
smoking, non- pregnant, and not taking any antibiotic medications or appetite 
suppressants.  
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Initial Screening/ Assessment:  
 During visit 1, individuals reported to the energy balance laboratory and 
consisted of screening, completion of informed consent, instruction about study 
protocol, and body composition assessment.  Body composition was assessed via 
BOD POD. Procedure for use of BODPOD is outlined elsewhere.  At the 
completion of visit 1, subject was scheduled for baseline assessment to occur on a 
Tuesday.   
Baseline Assessment: 
 During visits two and four, baseline measurements were performed.  Visit 2 
was prior to any dietary intervention-taking place. And visit four took place 
following an 11-day washout period.  Participants arrived at the lab following a 
10- hour fasting period.  Fasting anthropometrics, blood glucose, and breath 
hydrogen were taken. Subjective appetite was assessed via visual analogue scales 
(VAS) under fasting conditions.  Individuals were then given a high- FODMAP 
test meal (described below).  Blood glucose, breath hydrogen, and appetite 
questionnaires were reassessed at 30 minutes and 60 minutes post completion of 
the test meal.  At the conclusion of the laboratory session, subjects, were randomly 
assigned to follow either the high FODMAP (Diet 2) or low FODMAP (Diet 1) 
diet for a period of three days.  
Post-Intervention Assessment: 
 Post- Intervention testing consisted of visits three and five and took place after 
the subject had been following the dietary intervention for a period of three days.  
Since baseline assessment took place on a Monday, post-intervention testing took 
place on Friday.  Laboratory protocols, for post-intervention assessment, was 
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identical to that of baseline assessment.  Subjects received a total of eighty dollars 
for their participation in the study.  Twenty dollars was paid after session three and 
sixty dollars was paid after the fifth and final visit.   
High-FODMAP Test Meal:  
The test meal was designed to mimic real world conditions. The 25g of 
FODMAPS associated with the test meal has been found to induce increases in 
breath hydrogen concentration indicating carbohydrate malabsorption 9. The 
administration of this test meal should be sufficient to observe the postprandial 
physiological response associated with a high FODMAP conditions in the 
laboratory setting.  The test meal will consist of: 2 pieces of whole grain bread, 1 
tsp. of sugar free preserves, 1 tsp. of honey, 40 g of raisins, and 12 oz. of milk.  
This meal consists of 478 kcal and contains 25g of FODMAPs per serving (see 
appendix F for complete nutritional information). Nutritional information 
regarding test meal was determined through the use of Nutritional Data System for 
Research (NDSR) (2012, Nutrition Coordinating Center (NCC), University of 
Minnesota, Minneapolis, MN).   
Educational Material:  
 To assist with dietary adherence, each participant received educational material 
regarding the assigned diet.  The educational material came in the form of a 
booklet that assisted the participant in choosing foods included in their particular 
diet conditions.   The educational material contained “foods to eat” and “foods to 
avoid” for each food group (see sample in Appendix G). The educational material 
utilized during this study was created specifically for the purposes of this study 
utilizing previous research2,33-35. Educational materials regarding low FODMAP 
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conditions will emphasize the reduction in consumption of fructose, lactose, 
fructans, and polyols, as these are common in the western diet 2.  For example, the 
low FODMAP diet stressed utilization of sucrose and glucose as sweeteners 
instead of high-fructose corn syrup, fructose, isomalt, sorbitol, corn syrup, and 
honey 2.    Educational materials regarding the high FODMAP diet directly 
opposed that of the low FODMAP conditions and encouraged the consumption of 
foods containing these carbohydrates.  These educational materials helped 
participants incorporate high or low FODMAP conditions into their normal, free-
living diet. 
Breath Hydrogen:  
 Breath hydrogen was analyzed 3 separate times during laboratory sessions 2-5.  
Fasting values, 30 minute, and 60-minute post meal data will be obtained.  
Samples were collected with the QuinTron AveoSampler (QuinTron Instrument 
Co, WI, USA).  Collection of sample required that participants inhale maximally, 
hold breath for a period of 15 seconds, then expel breath into AveoSampler 
collection device.  Experimentally, this method has shown to allow for adequate 
respiratory exchange to occur resulting in more accurate and reproducible results 
30
.  Once obtained, samples will be immediately analyzed utilizing the QuinTron 
Microlyzer- CM (Serial number: 106-410-05, QuinTron Instrument Co, WI, USA).  
The instrument will be calibrated 30 min prior to use, utilizing 98-PPM reference 
gas (Lot Number: 37083, QuinTron Instrument Co, WI, USA) 31,32.  Samples, at 
each time point, were collected in duplicate and the results averaged.  
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 Use of a QuinTron Microlyzer is a validated means through which breath 
hydrogen can be assessed. QuinTron has been determined to be the gold standard 
for detecting a positive breath hydrogen test (sensitivity= 0.90 and Specificity= 
0.95) 31.  Furthermore, QuinTron Microlysers have been used as a means to 
validate other means of breath hydrogen analysis 31.  
Blood Glucose:  
 Blood glucose was analyzed at 3 separate points during each laboratory 
session. Capillary blood from subjects fingers was utilized for this analysis and 
was sampled at 0 minutes (Fasting), 30- minutes post-test meal, and 60-munutes-
post test meal. Protocols for obtaining capillary blood samples were obtained from 
Alere Inc.  Lithium heparin capillary tubes (Lot number: 2221, Alere INC) were 
utilize to collect 40 µL aliquots of capillary blood at each time point.  Blood 
samples were immediately analyzed using a Cholestech LDX (Serial No. 
SNAA122881, Alere Inc., Waltham MA).   Analysis shows that data provided by 
Cholestech LDX meets accuracy and precision definitions set by the National 
Cholesterol Education Program111,112.  These studies demonstrated that the 
Cholestech LDX is a valid means through which capillary blood samples can be 
analyzed 111,112.  
Appetite/Satiety:  
 Appetite and satiety were assessed using visual analog scales (VAS).  During 
laboratory sessions participants filled out VAS questionnaires regarding satiety, 
appetite, thirst, and prospective food consumption (see appendix E). VAS has been 
determined to be an effective method for assessing appetite and satiety 25.  Flint et 
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al. established a direct correlation regarding VAS scores and subsequent energy 
intake amongst participants 25.   
 Anthropometrics: 
 All anthropometric measurements will be obtained at the beginning of each 
laboratory session, after the participant had voided bladder and had undergone a 
10-hour overnight fast.  Height will be measured to the nearest 0.1cm utilizing a 
stadiometer (Serial No. 110818-002, Quick Medical, Issaquah, WA). Height will 
be measured two times and averaged together, however, if measurements have a 
difference of greater than 0.2 cm then the measurement will be repeated until two 
measurements are within this range. Weight will be measured in duplicate to the 
nearest 0.1 kg using a digital scale (Health-O-Meter, Model 752KL, Northbrook, 
IL).  If there is greater than 0.2 kg difference, then the measurement will be 
repeated until two measurements are within this range. Body mass index (kg/m2) 
will then be calculated utilizing these two measurements.  Waist circumference 
will be measured using a standard tape measure with tensometer.  Measurement 
will be obtained by placing the tape measure around the participant’s waist at the 
level of the umbilicus. If there is greater than 0.5 cm difference, then the 
measurement will be repeated until two measurements are within this range. 
Protocol utilized for collection of anthropometric data has been described 
elsewhere 33. 
Sample Size: 
 Sample size calculations were performed based on differences in blood glucose 
response seen in a previous study by Nilsson et al 39. This study found that peak 
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blood glucose concentrations decreased 1mmol/L (18 mg/dl) from control to 
experimental conditions. Calculations show an effect size of 3.33. All calculations 
were based on an alpha of 0.05 and power of 0.80, and were completed using G* 
Power (version 3.1.7). According to these calculations, a 8-person sample size 
would be adequate to achieve sufficient power.  Therefore, the proposed sample 
size of 16 will provide appropriate statistical power for measuring changes in 
blood glucose response in healthy individuals.   
Data Analysis: 
 All data was analyzed using SPSS version 21.0 (IBM Corp, Released 2012 
Armonk, NY).  Skewness and Kurtosis were calculated to determine normality of 
the data.  All data met criteria for normality.  Comparison of between diet blood 
glucose, breath hydrogen, and VAS scores at different time points (0,30,60 min) 
were made through the use of a 2x2 repeated measures analysis of variance.  Post 
hoc t-test were utilized.  Analysis of within-treatment effects were examined via 
paired- t-test for all outcomes. Total Area under the curve was calculated for blood 
glucose utilizing trapezoid method113. Analysis of categorical data was performed 
utilizing chi-square.  
Resources Required:  
 Funding for this research came from a grant that was obtained by Dr. Kathleen 
Melanson from the Research Dietetics Practice Group of the Academy of Nutrition 
and Dietetics. Laboratory supplies for this study included AveolarSampler test 
kits, Alere Lipid Profile*GLU cassettes, food for test meal, and a stipend of $80.00 
that was paid to each subject.  Supplies provided by the Department of Nutrition 
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and Food Sciences, will include NDSR, QuinTron Microlyser, anthropometric 
equipment, Cholestech LDX, computers, and software for data analysis. No other 
university resources were required.     
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C. MACRONUTRIENT CONTENT OF TEST MEAL 
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D. Breath Hydrogen Collection Protocol  
Warm Up Period 
1. Turn on system 15 minutes (at least) prior to use.  
2. Following the warm up period, adjust the front panel labeled “parts per 
million” until it reads “000” 
 
Calibration 
  Materials needed- Reference gas, SivRite cartridge, syringe, stopcock 
1. Pull “out” valve stem so that pilot light turns GREEN 
2. Using a syringe with stopcock, extract 20 ml of reference gas (concentration of 
98 ppm).  
3. Place the SivRite cartridge directly into the flush port. 
4. Inject the reference gas into the machine via the SivRite cartridge.  (if 
reference gas cannot be injected, check to make sure A-the valve stem is pulled 
all the way out and B- the stopcock is open.) 
5. After the gas has been flushed, push the valve stem “in” until the GREEN light 
changes to RED and observe the meter response.  
6. Once the meter response becomes stable, adjust the “calibrate” knob until it 
reads “098”. 
7. Pull the valve stem “out” and the meter response should read “000”. 
8. If meter response does not read “000”, re-zero the instrument and repeat 
calibration process. 
9. Continue process until instrument is properly calibrated 
 
Collection/ Analysis of Sample: 
  Materials needed- Breath Collection kit (including mouth piece, 
collection   bag and discard bag), SivRite cartridge, syringe, stopcock 
1. Ask subject to take deep breath and hold breath for 15 seconds. 
2. After 15 second has passed, have subject exhale normally 
3. As individual is exhaling, withdraw 20 mL of expelled air via the syringe with 
stopcock. 
4. Pull the valve stem “out” so that the pilot light turns GREEN 
5. Inject 20 ml of the sample gas into the machine via the SivRite Cartridge 
6. Push valve stem “in” until the light turns RED 
7. Record the H2 concentration (ppm) presented in the meter response 
8. Pull Valve stem “out” so that light turns GREEN and release the sample from 
the port 
9. Using the syringe, back flush 40 ml of room air into the machine. 
10. Repeat analysis using an additional 20 ml taken from the original collection 
bag.  
11. Take the average of the two numbers 
 
 This process can be done after the participant has left. Samples are good for 2-
3 hours in the breath collection bag  
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E. IN-LAB DATA COLLECTION SHEETS 
NAME ____________________ 
 
The Carb Study 
Participant Screening Form 
Inclusion Criteria: 
YES        NO    Healthy, not experiencing symptoms of any illness such as a cold or flu 
YES        NO  Not currently on a weight loss diet 
Exclusion Criteria: 
YES        NO               Food Allergy     
                            If Yes _________________ 
YES        NO               Hypolactasia (Lactose Intolerance) 
YES        NO               Celiac Disease 
YES        NO               Gluten Intolerance 
YES        NO               Current smoker  
YES        NO               Irritable Bowel Syndrome 
YES        NO               Pregnant or lactating 
YES        NO   Type 1 or Type 2 Diabetes Mellitus  
YES        NO              Diverticular Disease 
YES        NO              Colitis such as Crohn’s disease or Ulcerative Colitis 
YES        NO    Adrenal disease 
YES        NO    Hypoglycemia (low blood sugar) 
YES        NO    Seizures 
YES        NO    Kidney or bladder problems 
YES        NO    Stomach ulcers 
YES        NO    Thyroid diseases 
YES        NO               Currently taking appetite suppressant medication 
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Subject #/ ID Condition ID Visit # Date 
  1 
 
 
Investigators Present:______________ 
Initial Assessment 
Screening Tool and Consent Form  
 ___ Eligibility Verified using screening tool 
 ___ Informed consent explained and both forms signed by subject 
&  investigator.  
BodPod 
 Body fat percentage as measured by BodPod. Record 
measurements to one  decimal place (.0%)   ____ % 
Demographics 
 Age:___ 
 Gender:____ 
Contact Information/Preferred Means of Contact 
  ___ Email:   ____________________________ 
  ___ Cell phone:  __________________ 
  ___ Text 
Visit 2 Scheduling 
___ Inform subject that they must refrain from eating or drinking anything 
except water before reporting to the lab for their next visit 
  Visit 2 must be scheduled on a Tuesday and after a 10 hour 
fast. That being said, the date of the participant’s next appointment will 
be: 
   Tuesday, __________________ at _______ A.M. 
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Subject #/ ID  Diet # Visit # Date 
  2 
 
 
 Investigator/s Present: 
____________ 
PREIntervention 
Time: _______ 
___ 10 hour fast verified. 
___ Subject voided bladder. 
Fasting Values 
Height (cm) ______  Height (cm) _______  Ave. ________    /100 =   
________ m    
                        m
2
 =  
________ 
Weight (lb) _______  Weight (lb) _______   Ave. ________     /2.2 = 
________ kg 
BMI (kg/m²) ________ 
WC (cm) _______    WC (cm) _______      Ave. ________ cm    
___ Give Appetite Questionnaire #1 
Breath Hydrogen Concentration Results: 
 BH2 _______ppm    BH2 _______ ppm     Ave H2. ________ ppm 
Capillary Glucose Concentration Result:_____ mg/dL.   
Test Meal 
___ Give prepared Test Breakfast and record the following times: 
  Start Time ___:___:___ 
  Meal completion: ___:___:___    
  30 minutes post meal completion time: ___:___:___  
  1 hour post meal completion time: ___:___:___ 
___ Start Timer  
___ Tell subject that they must remain in the lab for 1 hours with no food 
or drink. 
___ 24-hour recall 
 
30 minutes after meal completion time 
___ Appetite Questionnaire #2 
Breath Hydrogen Concentration Results: 
 BH2 _______ppm    BH2 _______ ppm     Ave H2. ________ ppm 
Capillary Glucose Concentration Result:_____ mg/dL.   
 
___ Explain and give subject information regarding assigned Diet #____ 
  71
 
1 hours after meal completion time 
___ Give Appetite questionnaire #3 
Breath Hydrogen Concentration Results: 
 BH2 _______ppm    BH2 _______ ppm     Ave H2. ________ ppm 
Capillary Glucose Concentration Result:_____ mg/dL.   
 
 
 
 
 
 
Visit 3 Scheduling 
___ Inform subject that they must refrain from eating or drinking anything 
except water before reporting to the lab for their next visit 
 
  Visit 3 must be scheduled on Friday and after a 10 hour fast. 
That being said, the date of the participant’s next appointment will be: 
   Friday, __________________ at _______ A.M. 
 
 
 
___ Describe any unusual events:   
 
- about the subject: was sick, didn’t follow directions, didn’t like test meal, 
remarks/questions about the study. Equipment malfunctions 
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Subject #/ ID Diet # Visit # Date 
  3 
 
 
 Investigator/s Present: 
____________ 
POST-Intervention 
Time: _______ 
___ 10 hour fast verified. 
___ Subject voided bladder. 
Fasting Values 
Height (cm) ______  Height (cm) _______  Ave. ________    /100 =   
________ m    
                        m
2
 =  
________ 
Weight (lb) _______  Weight (lb) _______   Ave. ________     /2.2 = 
________ kg 
BMI (kg/m²) ________ 
WC (cm) _______    WC (cm) _______      Ave. ________ cm    
___ Give Appetite questionnaire #1 
Breath Hydrogen Concentration Results: 
 BH2 _______ppm    BH2 _______ ppm     Ave H2. ________ ppm 
Capillary Glucose Concentration Result:_____ mg/dL 
Test Meal 
___ Give prepared Test Breakfast and record the following times: 
  Start time: ___:___:___  
  Meal completion:___:___:___ 
  30 minutes post meal completion time:___:___:___   
  1 hours post meal completion time: ___:___:___  
___ Start timer 
___ Tell subject that they must remain in the lab for 1 hours with no food 
or drink. 
___ 24-hour recall 
 
30 minutes after meal completion time 
___ Give Appetite Questionnaire #2 
Breath Hydrogen Concentration Results: 
 BH2 _______ppm    BH2 _______ ppm     Ave H2. ________ ppm 
Capillary Glucose Concentration Result:_____ mg/dL.   
 
   1 hours after meal completion time 
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___ Give Appetite Questionnaire #3 
Breath Hydrogen Concentration Results: 
 BH2 _______ppm    BH2 _______ ppm     Ave H2. ________ ppm 
Capillary Glucose Concentration Result:_____ mg/dL.   
___ Subject received $20. 
 
Visit 4 Scheduling 
___ Inform subject that they will now have an eleven-day washout period 
where they should not follow any specific diet (eat what they usually eat) 
___ Inform subjects that they must refrain from eating or drinking 
anything except water before reporting to the lab for their next visit 
  Visit 4 must be scheduled eleven days from now on Tuesday 
and after a 10 hour fast. That being said, the date of the participant’s next 
appointment will be: 
 
   Tuesday, __________________ at _______ A.M. 
 
___ Describe any unusual events:   
 
- about the subject: was sick, didn’t follow directions, didn’t like test meal, 
remarks/questions about the study  
- equipment malfunctions 
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F. QUESTIONNAIRES 
Energy Balance Lab Satiety Rating Scale 
Subject #/ ID Condition ID Visit # Date 
   
 
 
  
 Clock Time: ________ (0) 
 
1.  How hungry are you right now? 
 
Not at all      Extremely 
 
2. How satisfied (satiated) are you right now? 
Not at all      Extremely 
 
3. How much could you eat right now? 
Nothing        Vast Quantities 
 
4. How thirsty are you right now? 
Not at all      Extremely 
 
 
 5.   A)  Are you currently suffering from any abdominal discomfort?     Yes   No 
 
  B) If yes, how severe is the abdominal discomfort? 
        No pain              Severe 
Discomfort 
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Energy Balance Lab Satiety Rating Scale 
Subject #/ ID Diet Visit # Date 
   
 
 
  
 Clock Time: ________ (30) 
 
1.  How hungry are you right now? 
 
Not at all      Extremely 
 
4. How satisfied (satiated) are you right now? 
Not at all      Extremely 
 
5. How much could you eat right now? 
Nothing        Vast Quantities 
 
4. How thirsty are you right now? 
Not at all      Extremely 
 
 
 5.   A)  Are you currently suffering from any abdominal discomfort?     Yes   No 
 
  B) If yes, how severe is the abdominal pain? 
        No pain              Severe 
Discomfort 
Energy Balance Lab Satiety Rating Scale 
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Subject #/ ID Diet Visit # Date 
   
 
 
  
 Clock Time: ________ (60) 
 
1.  How hungry are you right now? 
 
Not at all      Extremely 
 
6. How satisfied (satiated) are you right now? 
Not at all      Extremely 
 
7. How much could you eat right now? 
Nothing        Vast Quantities 
 
4. How thirsty are you right now? 
Not at all      Extremely 
 
 
 5.   A)  Are you currently suffering from any abdominal discomfort?     Yes   No 
 
  B) If yes, how severe is the abdominal pain? 
        No pain              Severe 
Discomfort 
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G. DIETARY INSTRUCTION BOOKLETS 
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H. Consent Form for Research 
 
 
The University of Rhode Island 
Department of Nutrition and Food Sciences 
Kingston, RI 02881 
The Carb Study 
 
CONSENT FORM FOR RESEARCH 
 
You have been invited to take part in a research project described below.  
The researcher will explain the project to you in detail.  You should feel 
free to ask questions.  If you have more questions later, Kathleen 
Melanson, the person mainly responsible for this study, will discuss them 
with you (Energy Balance Lab, 310 Ranger Hall, 401-874-2067).  You 
must be at least 18 years old to be in this research project. You will also 
need to be available for two Tuesday and two Friday mornings for testing. 
 
Description of the project: 
You have been asked to participate in a research study designed to test the 
acceptability of and physiological responses to the manipulation of dietary 
carbohydrate sources. 
 
What will be done: 
Following an initial assessment visit, all study volunteers will follow two 
specific diets for three days each, with 11 days of your normal eating in-
between:  
• You would follow the first diet for three days between the second 
lab and third lab visits.   
• During the 11-day period between the third and fourth lab visits, 
you would not be asked to follow any specific diet; you would just 
return to your normal diet.  
• You would follow the second diet for three days between the fourth 
and end the fifth lab visits, which marks the end of the study. 
 
Total time in the lab will amount to about 8.5 hours: 30 minutes for first 
visit, and about two hours each for the other four visits. You will note 
below that the two-hour visits include a one-hour wait between 
consumption of a test breakfast and the second round of measurements.  
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While some of this wait period will be used to perform a 24-hour dietary 
recall (visits 2-5) and give instructions for your assigned diet (visits 2 and 
4), these activities are not likely to consume the whole 1 hour waiting 
time. For that reason, it is recommended that you bring homework or 
some form of activity to occupy yourself between measurements.   
 
Your total compensation for completing the study will be $80. You will 
receive $20 following the third lab visit, after completion of the first test 
diet.  You will receive the remaining $60 following the fifth and final lab 
visit, after completing the second test diet and concluding your 
participation in the study. 
 
• First Visit (~30min) 
o We will ensure your eligibility for this study by verifying your 
age and the absence of exclusionary criteria. 
o We will explain to you what this study entails and what will be 
expected of you as a participant in this study. 
o After you have had a chance to ask any questions, you will be 
given a consent form to fill out. 
o Upon completing the consent form and agreeing to partake in 
the study, you will have your body composition measured using 
the BodPod. 
 You will be asked to sit inside the BodPod machine and 
comfortably rest for 2-5 minutes while your body fat 
percentage is estimated.  This machine is a large egg-
shaped capsule, with a hatch that has an internal ‘panic 
button’ in case you want to open the hatch while you are 
in there.  For this test, we will ask you to bring a bathing 
suit to wear while you are in the BodPod.  This simply 
minimizes the chances that bulky clothing will affect the 
reading.  We will provide you with a swimming cap to 
place over your hair; this also minimizes the chances that 
air caught around your scalp would affect the reading.  
Your body fat is estimated in this fashion by calculating 
the amount of air you displace inside the known area of 
the BodPod.  This test should take less than 20 minutes. 
  
• Second Visit (~3hrs) 
o You will report to the lab following an overnight (10-hour) fast. 
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o Your height, weight, and waist circumference measures will be 
taken. 
o You will be asked a short series of questions regarding your 
appetite. 
o You will have a small amount of blood taken by fingerstick to 
measure your blood glucose concentration. 
o You will have your breath hydrogen measured by exhaling into 
a small bag. 
o You will eat a test breakfast. 
o 30 minutes following the breakfast, your blood glucose will be 
measured again and you will again be asked to answer questions 
regarding your appetite. 
o two hours following the breakfast, your blood glucose and 
breath hydrogen measurements will be taken again, and you will 
again be asked to answer questions regarding your appetite. 
o During the two hours between finishing the breakfast and the 
second round of tests, you will be asked to recall what you have 
had to eat and drink in the past 24 hours. 
o Following the 24-hour recall, you will be given instructions 
pertaining to the diet to which you have been assigned for the 
first leg of the experiment. You will also receive reference 
materials you can take with you to help you adhere to the 
assigned diet. 
 
You will be asked follow the assigned diet to the best of your ability for 
three days, beginning after you leave the lab up until 10 hours before the 
third lab visit. On each of these days you will complete short 
questionnaires about your appetite, how you feel, and your opinion of the 
diet.  For the 10 hours before the third visit, you will be asked to again 
refrain from eating or drinking anything except water before reporting to 
the lab for the third visit. 
 
• Third Visit (~2hrs) 
o You will report to the lab following an overnight (10-hour) fast. 
o Your height, weight, and waist circumference measures will be 
taken. 
o You will be asked a short series of questions regarding your 
appetite. 
o You will have a small amount of blood taken by fingerstick to 
measure your blood glucose concentration. 
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o You will have your breath hydrogen measured by exhaling into 
a small bag. 
o You will eat a test breakfast. 
o 30 minutes following the breakfast, your blood glucose will be 
measured again and you will again be asked to answer questions 
regarding your appetite. 
o Two hours following the breakfast, your blood glucose and 
breath hydrogen measurements will be taken again, and you will 
again be asked to answer questions regarding your appetite. 
o During the two hours between finishing the breakfast and the 
second round of tests, you will be asked to recall what you have 
had to eat and drink in the past 24 hours.  
 
Following the third visit, you will receive $20 in compensation for 
completing the first test diet. You may retain this payment even if you 
choose to withdraw before completion of the study.  There will be an 11-
day period during which you will not be asked to follow any specific diet. 
 
• Fourth Visit (~2hrs) will include the same procedures as the Second 
Visit. 
 
You will be asked follow the next assigned diet to the best of your ability 
for three days, beginning after you leave the lab up until 10 hours before 
the third lab visit. On each of these days you will complete short 
questionnaires about your appetite, how you feel, and your opinion of the 
diet. For the 10 hours before the third visit, you will be asked to again 
refrain from eating or drinking anything except water before reporting to 
the lab for the fifth visit. 
 
• Fifth Visit (~2hrs) will include the same procedures as the Third Visit. 
 
Following the fifth visit, you will have completed your participation in 
this study.  You will receive an additional $60 at the end of the fifth visit, 
for a total of $80 in compensation for completion of the study.  
 
 
 
 
Risks or discomfort: 
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There are no known risks for the following procedures: questionnaires, 
consumption the manipulated carbohydrate diets, measures of height, 
weight, waist circumference, body composition, breath hydrogen, food 
intake and appetite questionnaires. 
 
The finger prick can result in some slight, short term pain and discomfort. 
Even though trained, experienced personnel will perform the blood draw 
using sterile technique, it is possible that minor bruising and infection 
may occur.  
 
If during the course of the analysis, any incidental findings emerge that 
indicate a health risk to you (such as high fasting glucose levels), you will 
be informed and will be advised to consult with your personal physician.    
 
Benefits of this study: 
This study will help to determine the effects modified carbohydrate diets 
on several physiological factors relevant to clinical and therapeutic 
applications. The direct benefits to you include learning about your body 
composition, blood glucose, and diet.  Upon completing the first test diet 
you will receive $20.00 in compensation.  Upon completing the second 
test diet you will receive $60.00 in compensation, for a total of $80.00 for 
completion of the study.  
 
Confidentiality: 
Your participation in this study is confidential. All of your information 
will be coded by an identification number after all of your data have been 
collected.  None of the results of this study will identify you by name. The 
document linking your name and identification number and all data 
collected will be stored on password-protected computers and in locked 
file cabinets within the locked lab of the investigator. Access will be 
limited to study investigators.  Federal regulations require that data and 
signed consent documents be kept for three years following completion of 
the study. The researchers and the University of Rhode Island will protect 
your privacy, unless they are required by law to report information to city, 
state or federal authorities, or to give information to a court of law. 
Otherwise, none of the information will identify you by name. 
 
In case there is any injury to the subject:  
If you have any injury or discomfort as a result of the experiment, you 
should notify Dr. Kathleen Melanson at (401) 874-4477. You may also 
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call the office of the Vice President for Research, 70 Lower College Road, 
University of Rhode Island, Kingston, Rhode Island, telephone:  (401) 
874-4328. 
 
Decision to quit at any time: 
The decision to take part in this study is up to you. You do not have to 
participate. If you decide to take part in the study, you may quit at any 
time. Whatever you decide will in no way penalize you.  If you wish to 
quit, you simply inform Dr. Kathleen Melanson at (401) 874-4477 of your 
decision.  
 
Rights and Complaints: 
This study is part of research being conducted by the University of Rhode 
Island.  If you have any questions or if you are not satisfied with the way 
this study is performed, you may discuss your complaints with Dr. 
Kathleen Melanson (401) 874-4477, anonymously, if you choose. In 
addition, if you have questions about your rights as a research participant, 
you may contact the office of the Vice President for Research, 70 Lower 
College Road, Suite 2, University of Rhode Island, Kingston, Rhode 
Island, telephone: (401) 874-4328. 
 
You have read the Consent Form.  Your questions have been answered.  
Your signature on this form means that you understand the information 
and you agree to participate in this study.  
 
 
________________________  ________________________ 
Signature of Participant   Signature of Researcher 
 
_________________________  ________________________ 
Typed/printed Name    Typed/printed name 
 
__________________________  _______________________ 
Date      Date 
 
Please sign both consent forms, keeping one for yourself. 
 
Would you be willing to be contacted for future studies? If so, sign here: 
 
____________________________
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Fasting Blood Lipids for sample n=14 (mean± SD) 
 
 
 
Fasting cholesterol response at each time point (mg/dl). Change through each time point was assessed via 2x2 repeated measures ANOVA. 
Analysis via ANOVA did not produce any statistically significant results. Significant within treatment effects were seen during the high FODMAP 
diet for both triglycerides and LDL cholesterol.   
1: data was analyzed via repeated measures ANOVA. p-value and η2 are based on treatment*time interactions. 
Within treatment differences 
** = p <0.01 
* = p<0.05 
 
 
 
 
 
 
 
 
  Low-FODMAP diet High-FODMAP diet ANOVA1 
 
Baseline Day 3 ∆ Baseline Day 3 ∆ p-value   η
2
 
Total Cholesterol 149.5± 24.2 152.8±28.1 3.3 157.9± 25.9 158.7± 28.5 0.80 .645 .020 
Triglycerides 86.3± 21.2 76.3± 42.7 -10 120.9± 49.69 76.6± 19.6 -44.3** .065 .329 
HDL 57.0± 14.0 56.2± 18.7 -.80 56.9± 11.3 57.8± 13.2 0.90 .836 .004 
LDL 75.3±26.7 77.3±26.6 2.0 74.6± 28.6 83.7±33.1 9.10* .174 .195 98
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Fasting Blood lipids n=8 compliant with high-FODMAP diet (mean±SD) 
 
 
     Fasting cholesterol response at each time point. Change through each time point was assessed via 2x2 repeated measures ANOVA. Analysis 
via                             ANOVA did not produce any statistically significant results. Significant within treatment effects were seen during the high 
FODMAP diet for both triglycerides and LDL cholesterol. 
1: Indicates use of repeated measures ANOVA. p-value and η2 represent treatment*time interactions.  
 
  Low-FODMAP diet High-FODMAP diet ANOVA1 
 
Baseline Day 3 ∆ Baseline Day 3 ∆ p-value       η
2
 
Total Cholesterol 145.2± 20.7 142.4± 24.4 -2.8 157.7± 31.1 155.4± 36.3 -2.3 .927 .002 
Triglycerides 78.0± 16.7 63.8± 15.9 -14.2 130.6± 59.7     78.8± 15.4 -51.8 .083 .484 
HDL 60..0± 9.6 57.0±10.7 -3.0 63.8± 7.2 60.8± 12.17 -3.0 .976 .000 
LDL 69.8±17.1 71.1±20.6 1.3 70.6± 25.95 82.6±33.8 12.00 .133 .424 
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